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ABSTRACT 
DAWN PHILLIPS: Concurrent Validity and Responsiveness of the Peabody 
Developmental Motor Scales - 2(PDMS-2) in Infants and Children with Pompe 
Disease undergoing Enzyme Replacement Therapy                                     
(Under the direction of Angela E. Rosenberg, PT, Dr PH) 
 
 
 Purpose: To examine the responsiveness of the PDMS-2 in children 
diagnosed with Pompe disease who had different levels of functional mobility. To 
examine the concurrent validity between the PDMS-2 and the Alberta Infant 
Motor Scale (AIMS), the Pediatric Evaluation of Disability Inventory (PEDI) and 
the Pompe PEDI (PPEDI) in children diagnosed with Pompe disease. Methods: 
A secondary analysis was completed of the Genzyme Corporation Pompe 
efficacy trials for Myozyme. The children were divided into two functional groups, 
independent ambulators (group 1), and children who required use of assistive 
devices to ambulate or were unable to ambulate (group 2).   Results: A 
significant difference was present between the mean PDMS-2 subtest and Gross 
Motor Composite percentage scores at baseline and at week 52 when the whole 
group was combined. Responsiveness measured by the factor of Time and 
Function revealed Locomotion subtest statistically significant mean percentage 
change within both functional groups from baseline to week 52 and between 
groups at both time periods. No significant within group or between group 
differences were seen for the Stationary subtest. The Object Manipulation 
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subtest demonstrated significant change within group one from baseline to week 
52 and between the functional presentations at week 52.The age equivalent 
correlations between the PDMS-2 and AIMS indicate a good to excellent 
relationship for all subtests except the Object Manipulation subtest. A four-month 
range in age equivalent scores was necessary to achieve 100% agreement 
between the AIMS and the PDMS-2. Correlations between the PDMS-2, 
Locomotion and Stationary subtest and PPEDI for all age groups were in the 
moderate to good and good to excellent range.  Non-significant correlations were 
found for the Reflex and Object Manipulation subtest. Conclusions: The PDMS-
2 gross motor subtests were responsive to change in a heterogeneous group of 
children diagnosed with Pompe disease.  Responsiveness concerns were 
identified in the Object Manipulation and Stationary subtest when the children 
were divided into two different functional groups. A stronger relationship was 
present between the PDMS-2 and AIMS age equivalent scores than the 
percentile scores. Motor capacity on the PDMS-2 reflects actual performance in 
the home and community environment as measured by the PPEDI. 
 
 
 
 
 
 
 
 
 iv 
 
 
 
Dedication 
 This doctoral dissertation is dedicated to my husband Troy and our 
children Aubrie and Georgina. Without their support and encouragement 
completion of this dissertation would not have been possible.  I am also grateful 
for my mother, Myrna and for the many friends who have supported me and 
helped me to navigate the PhD process. Lastly I dedicate this dissertation to the 
children and families who live everyday with Pompe disease. They have been my 
best teachers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
 
 
TABLE OF CONTENTS 
            
Chapter I.  
Introduction  
 Background………………………………………………………………..   9   
           PDMS-2…………………………………………………………… ……. 12  
  1. Responsiveness………………………………………………. 12  
 2. Concurrent Validity……………………………………………. 13 
 3. Construct Validity……………………………………………… 17 
           Pompe Disease and the AGLU0 1602 and 1702 Clinical Trials……. 18 
Purpose and Implications of Research………………………………… 21 
Operational Definitions………………………………………………….. 24  
References……………………………………………………………….. 26 
Chapter II.  
Gross Motor Development of Children with Pompe Disease with                       
Variable Levels of Functional Mobility - Use of the Peabody       
Developmental Motor Scales - Second Edition 
  Introduction……………………………………………………….. 28 
  Purpose…………………………………………………………… 33 
  Research Questions…………………………………………….. 33 
  Participants……………………………………………………….. 34 
  Procedure…………………………………………………………. 37 
   PDMS-2…………………………………………………… 38 
  Data Analysis………………………………………………………39 
  Results……………………………………………………………. 40 
 vi 
   Locomotion………………………………………………. 41 
   Object Manipulation……………………………………… 41 
   Stationary…………………………………………………. 42 
   GMC……………………………………………………….. 42 
  Discussion………………………………………………………… 42 
   Application to Clinical Practice and Use in Research…46 
   Limitations………………………………………………… 48 
  Conclusion………………………………………………………... 48 
References……………………………………………………….. 54  
Chapter III.   
Concurrent Validity of the Peabody Developmental Motor  Scales-              
Second Edition and the Pediatric Evaluation of Disability Inventory,                   
the Pompe Pediatric Evaluation of Disability and the Alberta Infant                
Motor Scale 
  Introduction……………………………………………………… 56 
  Pompe Disease………………………………………………….. 61 
  Purpose…………………………………………………………… 63 
  Research Questions…………………………………………….. 64 
  Participants……………………………………………………….. 65 
  Procedure………………………………………………………… 66 
   PDMS-2…………………………………………………… 66 
   AIMS………………………………………………………. 67 
   PEDI and PPEDI…………………………………………. 68 
  Data Analysis…………………………………………………….. 69 
  Results 
   PDMS-2 and AIMS……………………………………… 69 
   PDMS-2 and PPEDI/PEDI.......................................... 70 
   PPEDI and AIMS………………………………………… 71 
 vii 
   PPEDI and PEDI………………………………………… 72 
  Discussion 
   PDMS-2 and AIMS……………………………………… 72 
   PPEDI…………………………………………………….. 75 
   Eligibility for Services……………………………………. 76 
   Limitations……………………………………………….. 78 
  Conclusion………………………………………………………... 78 
  References………………………………………………………. 82 
Chapter IV.  
Synthesis          
 Summary of Results………………………………………………………84   
 Application to Clinical Practice and Research………………………… 89   
 Limitations and Future Research………………………………………. 91   
 References……………………………………………………………….. 93 
Appendix One: Literature review          
 PDMS-2…………………………………………………………………… 94 
 Pompe Disease/ ALGU0 1602 and 1702 Clinical Trial ……………..102  
  Administrative Procedure for the AIMS, PEDI, PPEDI, &                  
       PDMS-2…………………………………………………………. .106 
  Additional Instruments                                                                       
  AIMS ……………………………………………………………..107 
  PEDI……………………………………………………………….108 
            PPEDI……………………………………………………………..109           
  Summary…………………………………………………………………111 
  
 References………………………………………………………………..114 
 
 
 
 
 viii 
 
 
 
List of Tables          
   
Chapter II.  
 Table 1. Gender and Age Distribution by Functional Classification… 49 
 Table 2. PDMS-2 Scores for Older Subjects in Functional Group … 49           
     Two    
 Table 3. Responsiveness of PDMS-2a Individual Subtest and …….. 50    
     GMCb Percentage Scores from Baseline to Week 52;      
      Functional Group One and Two Combined 
 Table 4. ANOVA Results for PDMS-2a Individual Subtests and……. 50  
      GMCb Percentage Scores Factors:  
 Table 5. Results of Post Hoc Analysis of Locomotion Subtest by …. 51  
      Time and Functiona,with Responsiveness Indices 
 Table 6. Results of Post Hoc Analysis of Object Manipulation …….. 51    
      (OM) Subtest by Time and Functiona, with                
               Responsiveness Indices 
 Table 7. Results of Post Hoc Analysis of Stationary Subtest ………. 52      
     by Time and Functiona, with Responsiveness Indices 
 Table 8. Results of Post Hoc Analysis of Gross Motor Composite … 52    
     by Time and Function a, with Responsiveness Indices 
 Table 9. Example of PDMS-2a Raw Scores at Baseline and Week… 53    
     52 for Two Subjects 
Chapter III. 
Table 1. Pearson Product Moment Correlation Coefficients (r) for…. 79            
    the Age Equivalent and Percentile Scores of the                        
    PDMS-2 Subtests and GMC, and the AIMS  
 Table 2. Mean Age Equivalent and Percentile Rank Scores for…… 80  
      the PDMS-2 GMC and the AIMS   
 Table 3. Percent Agreement in Age Equivalent Scores for the…….. 80 
      PDMS-2 GMC and AIMS  
 ix 
 Table 4. Pearson Product Moment Correlation Coefficients(r)……… 81                   
       for the PDMS-2b Subtest Percentage Scores and the               
     PPEDI  Functional Skills Dimension Scaled Scale 
  
 
Chapter I.  
Introduction 
Background 
 Documentation of eligibility for service and efficacy of intervention with 
standardized assessment tools is increasingly being required for service 
reimbursement.  Eligibility for the North Carolina Infant Toddler Program currently 
requires children to have an established condition or developmental delay 
documented with scores of 2.0 standard deviations below the mean on 
standardized tests or 30% delay on instruments which use age equivalent test 
scores.1 The Guide to Physical Therapy Practice includes tests and 
measurements as an essential component in examination and evaluation, used 
to establish functional limitations, impairments and baseline information. 2 
Pediatric physical therapists are completing standardized assessments as part of 
their routine clinical practice with 59% reporting using a standardized measure 
daily or weekly.3  
 In a survey of pediatric physical therapists, the Gross Motor Function 
Measure 88 (GMFM), the Alberta Infant Motor Scale (AIMS) and the Peabody 
Developmental Motor Scales-2 (PDMS-2) were the three most commonly used 
pediatric motor outcome measurement tools.3 The PDMS-2 was designed to 
assess motor development in children from birth to 72 months of age.4 It is the 
only discriminative outcome assessment tool of the three tools listed that 
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provides normative comparison data for children between 18 months and 72 
months of age. The AIMS is a discriminative tool designed to assess motor 
development and provide normative percentile ranking from birth to 18 months of 
age.5 The GMFM -88 is a criterion based assessment tool that does not provide 
a comparison to a normative sample.   The PDMS-2 measures fine motor and 
gross motor skills and the AIMS and the GMFM are measurements of gross 
motor skills only. 
 According to the manual, possible uses of the PDMS-2 include; 
“determination of motor competency relative to a normative peer sample, 
assessment of qualitative and quantitative capacities of individual gross motor 
and fine motor skills, evaluation of progress over time and determination of 
efficacy of interventions in research.”4 (page 8) The manual does not define 
appropriate use for specific diagnoses or levels of functional mobility. The PDMS-
2 is widely used in a variety of clinical settings including evaluation centers for 
the Infant Toddler Program,1 Preschools and Schools, therapy centers and 
specialty clinics. It is routinely used as part of interdisciplinary clinical 
assessments and research clinical protocols in the Program for 
Neurodevelopmental Function in Rare Disease Clinic at the University of North 
Carolina at Chapel Hill.6 Current use of the PDMS-2 includes a very wide range 
of developmental disabilities and functional presentations. The available literature 
on PDMS-2 focuses on typically developing children, and children at risk of 
developmental delay. There is a paucity of evidence to support the validity of use 
in children with chronic disease or significant developmental disability. 
 12 
 The validity of a tool is not an absolute value because it varies according 
to the purpose of use, and the population of subjects tested.7 An outcome 
measure is valid if it measures what it is designed to measure and accurately 
reflects the clinical findings.8 Validity has also been defined as the evaluative 
summary of the evidence for use and the potential consequences of score 
interpretation.7 Therefore, PDMS-2 test validity should be an ongoing process in 
order to define appropriate use with new populations. Test validity is necessary 
to accurately document disease history, evaluate efficacy of the intervention, and 
supplement clinical decision.  
 Validity of an outcome measurement tool can be assessed in terms of 
construct, content, and concurrent validity and responsiveness to change. 
Responsiveness can be defined as the ability to measure clinically important 
change over time.9 The validity of a tool impacts tool responsiveness because 
change depends on the fit between the tool operational definition and the item 
you are interested in measuring.  Concurrent validity is the method of evaluating 
criterion validity, the degree to which the instrument reflects or is related to 
scores obtained on a reference standard instrument. The concurrent validity 
between the PDMS-2 and other commonly used pediatric outcome measurement 
tools is inconclusive.10 Lack of agreement between outcome scores may change 
eligibility status for services between agencies and geographic regions and 
misinform efficacy intervention research. 
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PDMS-2 
 The PDMS-2 is a standardized norm referenced test for children from birth 
to 72 months of age.4 Four subtests make up the PDMS-2 gross motor 
composite, Reflexes, Stationary, Locomotion and Object Manipulation. The 
Reflex subtest is indicated only for subjects less than one year of age and the 
Object Manipulation subtest is used only after 12 months of age. All items are 
scored on a three point scale, with 0 indicating that the criteria for successful 
performance were not met, 1 indicating the behavior is emerging, and 2 
indicating successful performance of the item criteria.4 The PDMS-2 raw subtest 
scores are typically used to calculate standard percentile and age equivalent 
scores. The gross motor subtest standard scores are used to calculate the 
overall Gross Motor Quotient. PDMS-2 standard subtest scores and motor 
quotients are calculated using normative age data.  They are beneficial for 
identifying risk and level of developmental delay, but are not suitable for use in 
determining responsiveness.9   Subtest raw score comparisons cannot be made 
because the subtests all contain a different number of test items.  
Responsiveness 
 Wang et al (2006) evaluated the responsiveness to change of the PDMS 2 
for children with cerebral palsy over a three-month period by use of paired t-tests, 
effect size, standardized response mean and the Guyatt Responsiveness Index.9 
Subtest raw scores were used to calculate percentage scores for the subtests. 
Subtest percentage scores were then used to calculate gross, fine and total 
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motor composite percentage scores.  Paired t-tests demonstrated that a 
statistically significant change (p<. 001) was present between the gross, fine and 
total motor percentage scores over 3 months.  The effect size for the gross motor 
subtest percentage score was labeled as small at 0.2 according to Cohen 
standards.9 The standardized response mean for the gross motor composite was 
labeled as trivial at 0.9.  Information was not included on individual subtests 
within the fine or gross motor composites.   A review of the literature did not 
provide any additional research on the responsiveness of the PDMS-2 gross 
motor subtests or composite scores. 
Concurrent Validity 
 Concurrent validity has been evaluated between the PDMS-2 and other 
gross motor outcome measures in infants and children with typical development 
and risk for developmental delay.  PDMS-2 test developers evaluated concurrent 
validity between the PDMS-2 and the Mullen Scales of Early Learning (MSEL) for 
typically developing children. The MSEL provides a baseline measurement of 
cognition and motor development and includes gross motor, visual reception, fine 
motor and expressive and receptive language items.4 The largest correlation 
coefficients were present between the MSEL and the PDMS-2 Gross Motor 
Quotient (r=. 86.) and between the MSEL and Locomotion and Object 
Manipulation subtests (both r=. 90).4 The PDMS-2 Stationary subtest did not 
correlate significantly with the MSEL Gross Motor Scale.  
 15 
 Snyder et al (2008) examined the concurrent validity of the AIMS and the 
PDMS-2 gross motor subtests for infants at risk for motor delay who ranged in 
age from birth to eighteen months.11 The AIMS is an observation tool for 
examination of postural control in infants who range in age from birth to 18 
months.5 The AIMS purposes are to identify infants with developmental delay, to 
address the rate of motor development with repeated testing and identify infants 
with abnormal patterns of movement.5 The Pearson product moment correlations 
varied from r= .78 to. 97.  The most significant correlation coefficient of r=. 97 
was found for the Locomotion subtest in infants less than nine months of age.  
Snyder el al (2008) used the AIMS total score and the PDMS-2 raw scores for 
calculation of the correlations and did not include an examination of standard 
scores.11 Eligibility for early intervention services requires providers to 
demonstrate developmental delay relative to a normative peer sample, using age 
equivalent, percentile ranking, and standard scores. 
 Researchers have found that the Bayley Scales of Infant Development II 
(BSID-II) Psychomotor Index (PDI) and the PDMS-2 had the strongest 
concurrent agreement for the Locomotion subtest, and that inconsistency was 
present in the ability to determine significant delay with standard scores.10,12  The 
BSID-II PDI is a discriminative motor scale that is used to identify developmental 
delay in children who range in age from one month to 3.5 years. Provost et al 
(2004) found that more than 75% of the sample classified as significantly delayed 
on the BSID-II (PDI <=69) did not score in the classification of “very poor” (TMQ, 
=69) on the PDMS-2. The PDMS-2 Locomotion subtest showed a high age 
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equivalent correlation of r=. 97 with the BSID-II PDI.  The Locomotion subtest 
and the BSID-II PDI had an age equivalent agreement within three months of 
96%.  The Stationary and Object Manipulation subtests and the BSID-II PDI had 
an age equivalent agreement within 5 months of 90-95%. With a 5-month 
difference in age equivalence scores obtained using different measurement tools, 
a child may be deemed eligible for early intervention services with one tool and 
ineligible for services with use of another. In a 20-month-old child, a 5-month 
delay in gross motor skills supports a 25 % delay and eligibility for early 
intervention services. 
 Connolly et al (2006) also examined PDMS-2 concurrent validity and 
found low (r=. 30) and non-significant correlations between the standard scores 
on the PDMS-2 and the BSID-II in typically developing, twelve month old 
infants.10 No correlation was found between the age equivalent scores for the 
Stationary and Object Manipulation subtests but a high and significant correlation 
was found (r=. 71 P<. 05) between the age equivalent PDMS-2 Locomotion and 
the BSID-II motor scale.10 Lack of agreement between the two tests could 
represent variability in service eligibility.12 When tests are important for clinical 
decision-making and service eligibility, Provost recommends a very high level of 
correlation (r=. 95) between two tests that are used to qualify for services.12 
 Mayrand et al (2009) 13 examined the association between the PDMS-2 
Gross Motor scale and the Pediatric Evaluation of Disability Inventory (PEDI) 
Functional Skills Mobility domain in children with language impairment. The PEDI 
is a standardized instrument for children aged 6 months to 7.5 years that uses 
 17 
parent report to measure level of disability in self care, mobility and social 
function domains.  The Functional Skills Mobility domain contains 59 items that 
are relevant for daily independence in mobility function such as toilet, chair, 
wheelchair, bed, tub, and car transfers; bed mobility; indoor and outdoor mobility 
and stair ascent and descent. The study found a low correlation (r=. 23), and 
non-significance (p=0.15) between the PEDI Mobility domain and PDMS-2 GMQ 
for use with children with combined physical primary language impairment and 
mild motor impairment. Whereas the PDMS-2 is a motor outcome measure, the 
PEDI focuses on the degree to which impairment impacts function in activities of 
daily living.  Although motor capacity should reflect actual performance in ADL, 
Mayrand et al13 hypothesized that the PEDI may not have been sensitive enough 
to detect subtle motor impairment in children with primary language impairment. 
The authors suggested that a stronger agreement between the PDMS-2 and the 
PEDI may be present if evaluated in a population of children with more significant 
motor impairment than the children with primary language impairment. Research 
supports a high intra-class correlation coefficient (.91) for concurrent validity 
between the PEDI and the Gross Motor Function Measure (GMFM) in children 
with spastic cerebral palsy.14 The GMFM is tool designed to measure change 
over time in gross motor function in children with cerebral palsy. 14  
 Overall, when concurrent validity of the PDMS-2 is examined, literature is 
not available to compare the PDMS-2 to valid gross motor measurement 
instruments for children with a chronic disease or moderate motor impairment.10 
Wang et al found the PDMS-2 to have acceptable responsiveness to change in 
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the gross motor composite in children with cerebral palsy.9 The research did not 
include individual PDMS-2 subtests or investigate concurrent validity with other 
pediatric outcome measures. The available literature focuses on typically 
developing children and children at risk of developmental delay, and 
inconsistencies are evident with use of age equivalent scores.  
Construct Validity  
 Construct validity represents the degree to which a measure reflects an 
operational definition. The PDMS-2 is based on the Taxonomy of the 
Psychomotor Domain by Harrow.4 The Locomotion subtest is designed to  
measure movements to change location such as rolling, crawling and walking, 
the Stationary subtest to measure ability to control body within center of gravity 
and retain equilibrium and the Object Manipulation subtest to measure 
coordinated motor movements such as throwing, catching and kicking a ball.4   
 Construct validity can be reduced by item gaps or an inadequate number 
of items to measure the construct. The Stationary subtest includes items to 
measure balance in sitting and kneeling, but no items are included that capture 
standing balance or transitions in and out of standing.  The items progress from 
#19, maintaining balance in kneeling for 5 seconds, to #20, standing on one foot 
for 3 seconds.  Each item in the PDMS-2 has a normative age equivalence score 
recorded in months. The age equivalence score for item #19 is 13 months and 
for item #20 is 31- 32 months. Therefore, only one item is included with an age 
representation between 13 and 31 months. The Locomotion subtest, however, 
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does contain items that measure a child’s ability to lower from standing to sitting 
and ability to stand independently without support. In contrast to the Stationary 
subtest, the AlMS provides five items that qualitatively analyze stationary 
standing.5 
 The PDMS-2 test developers reported lower mean item discrimination 
coefficients for the Stationary subtest than the Locomotion subtest.4  Item 
discrimination, as it relates to the PDMS-2, evaluates the subtest’s ability to 
discriminate between different levels of function. In the Stationary subtest, the 
lowest discrimination coefficient (r=. 41) was found in the 36-47 months age 
group. The recommended administration Stationary subtest-starting place for the 
36-47 month group is item #20, standing on one foot. A large jump in activity 
level is required to progress from tall kneeling to standing on one foot and item 
precision can be decreased. Children who do not pass the next item may have 
ability close to the item passed or close to the failed item, but the true level 
cannot be determined.15 The Stationary subtest item gaps may reduce construct 
validity, lead to misinterpretation of intervention efficacy with inaccurate age 
equivalent and standard score representation and produce low concurrent 
validity values when comparisons are made to other pediatric motor outcome 
measurement tools. 
Pompe Disease and the AGLU0 1602 and 1702 Clinical Trials 
 Pompe disease is a rare lysosomal storage disease characterized by a 
deficiency of the enzyme acid alpha glucosidase (GAA).16 Lack of GAA causes 
accumulation of glycogen in cardiac, skeletal, and smooth muscle and central 
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nervous system tissue, leading to progressive cardiomyopathy, respiratory 
compromise, generalized weakness and hypotonia.16 The natural history of 
infantile onset Pompe disease typically leads to death by 1 year of age.17 
 The Genzyme Corporation Pompe disease ERT clinical trials, AGLUO 1602 
and AGLUO 1702, involved administration of ERT with recombinant human alpha 
glucosidase (rhGAA - Myozyme) to infants and children from birth to 42 months 
of age. The study’s primary objective was to evaluate the safety profile of rhGAA 
as determined by the proportion of patients alive and ventilator free over the 
course of the treatment. 17 A secondary efficacy endpoint was the effect of 
treatment on motor development from baseline, as measured by the AIMS and or 
the PDMS-2.17 The Pediatric Evaluation of Disability Inventory (PEDI) and the 
Pompe Pediatric Disability Inventory (PPEDI) measured the change in disability 
index from baseline. A control group was not used. Previously, an epidemiologic 
study of the natural history of Pompe disease was completed to provide a 
historical control for the AGLUO-1602 and AGLO-1702 clinical trials.18  
 Outcome measurement testing for AGLUO 1702 was completed at baseline 
and weeks 12, 26, 38, and 52.  The AGLUO1602 cohort completed testing at 
baseline and weeks 12, 26, 38, 52, 64, 78, 90, and 104. Participants in the 
AGLUO 1702 clinical trial had the PDMS-2 completed at every assessment 
period. The PDMS-2 was collected for the AGLUO 1602 participants only at 
baseline, at the first assessment period at or after one year of age, and then at all 
subsequent assessments.  
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 Numerous factors contribute to ERT response in infants and children with 
Pompe disease including age and severity of disease presentation, age of 
initiation of ERT, and GAA activity as measured by cross- reactive immunologic 
material (CRIM) and anti- rhGAA antibody titer levels.19 Infants who began ERT 
before 6 months of age, but were unable to form a native enzyme GAA, 
responded poorly to treatment in the trials, with no significant motor changes on 
the AIMS or PPEDI. Patients with a higher baseline median muscle GAA at 
baseline, a baseline age of less than 12 months of age, and better baseline 
motor scores had the best response to ERT.20 
 The AGLUO1602 summary manuscript by Kishnani et al (2007) reported 
that 100% of the infants survived to 18 months of age.17 Compared to the 
untreated historical control group, the risk of death was reduced by 99%, and use 
of ventilatory assistance was reduced by 88%.17 Thirteen of 18 children from 
AGLUO-1602 demonstrated motor and functional changes on the AIMS and 
PPEDI.  At week 52, seven children demonstrated the ability to walk 
independently, three children could pull to stand independently and walk hand 
held, and three children could sit and roll independently but were not able to 
demonstrate weight bearing in standing. 17 The remaining five subjects did not 
demonstrate clinically meaningful change on the AIMS or PPEDI.17  The children 
with the largest change scores on the AIMS also demonstrated the most 
substantial functional gains on all three PPEDI domains, self-care, mobility and 
socialization.17 
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 Sixteen of 21 children were alive at the end of 52 weeks in the AGLUO-
1702 clinical trial. 21 Five patients died before week 28 due to cardiac or 
respiratory failure. 21 At baseline, five children were invasively ventilated and two 
were noninvasively ventilated (via mask). Of the five children who were invasively 
ventilated, three remained ventilated 24 hours a day, one reduced ventilation to 
12 hours a day and one child died.  Nicolino et al (2009) documented an age 
equivalent motor change score in 13 of 21 children on the AIMS or PDMS-2, but 
no scores or data analyses were included in the manuscript for interpretation of 
change scores. 21 The authors reported that five children were able to walk 
independently and eight patients could sit independently. 21 The remaining eight 
patients made no significant motor development gains from baseline.21 
Purpose and Implications of this Research 
 The first purpose of this dissertation was to examine the responsiveness 
of the gross motor subtests of the PDMS-2, in children diagnosed with Pompe 
disease who participated in Enzyme Replacement Therapy (ERT). 
Responsiveness was examined by level of function in two groups of children 
diagnosed with Pompe disease; children who ambulate independently and 
children who require use of assistive devices to ambulate or are unable to 
ambulate. The second purpose was to examine the concurrent validity between 
the PDMS-2 and the AIMS, the PEDI, and the PPEDI in children diagnosed with 
Pompe disease.  
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 The dissertation involved secondary data analyses of children diagnosed 
with Pompe disease, from the Genzyme Corporation enzyme replacement 
therapy (ERT) clinical trials. The PDMS-2 was concurrently administered with the 
AIMS, PEDI and PPEDI to 18 subjects under the age of 7.2 months (AGLUO -
1602) and 21 children between 6 months and 42 months (AGLUO 1702). The 
PDMS II was collected but never analyzed in clinical trial manuscripts.  
 Motor gains in response to ERT have been documented in the literature 
without a defined level of meaningful change response.  The ALGUO 1602 and 
1702 data sets provided an opportunity to measure PDMS-2 gross motor 
responsiveness in children diagnosed with Pompe disease who were diverse in 
age and had a heterogeneous level of functional mobility. Only children who were 
documented as “motor responders” in the literature were included in the 
analyses. 
 The author hypothesized that the Stationary subtest would be less 
responsive than the Locomotion or Object Manipulation subtest and that 
responsiveness would be dependent on level of functional mobility. Lack of 
responsiveness was hypothesized in the group of children who have difficulty 
maintaining balance in standing, have delayed acquisition of independent 
walking and may require use of adaptive equipment or caregiver assistance to 
maintain standing or ambulate.  
 The AIMS and the PDMS-2 both provide normative scores and are 
commonly used in early intervention to determine eligibility for services. 
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 Variability in normative scores creates challenges in test interpretation for 
eligibility determination and interagency collaboration. Examination of concurrent 
validity in a sample of children diagnosed with Pompe disease may aid therapists 
in test interpretation and identification of tool strengths and limitations that are 
applicable to a larger range of developmental disabilities. The author 
hypothesized that the strongest PDMS-2 subtest relationship would be present 
between the Locomotion subtest and the AIMS. 
 A comprehensive evaluation for children diagnosed with Pompe disease 
should not be limited to assessments that evaluate capacity to perform motor 
skills in the clinic environment. Function should also be considered within the 
context of activity limitations and participation restrictions within the community, 
home, and school environment. This research provided an opportunity to 
determine whether motor capacity on the PDMS-2 and the AIMS reflects actual 
performance in activities of daily living on the PEDI and the PPEDI.  The author 
hypothesized that the PPEDI would have a stronger relationship with the PDMS-
2 than the PEDI and that the strongest PDMS-2 subtest relationship would be 
between the Locomotion subtest and the PEDI and the PPEDI Functional Skills 
Mobility dimension. 
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Operational Definitions: 
1. Validity will be defined as the evaluative summary of the evidence for 
use and the potential consequences of score interpretation. Validity of 
a tool is not an absolute value because it varies according to the 
purpose of use, and the population of subjects tested. 
 
2. Construct validity indicates the degree to which a measurement 
reflects an operational definition. The construct validity of an 
instrument may evolve over time with changes in the understanding of 
the construct of interest. 
 
3. Content validity defines the extent to which the items reflect a content 
domain and it is clear that no items are missing. 
 
4. Concurrent validity is the method of evaluating criterion validity, the 
degree the instrument reflects or is related to scores obtained on a 
reference standard instrument. Concurrent validity also evaluates the 
level of agreement that is present between two outcome 
measurements. 
 
5. Responsiveness can be defined as the ability to measure clinically 
important change over time. 
 
6. Minimal detectable change has been described as the amount of 
change that exceeds the standard error of the instrument. 
 
7. AGLUO 1702: Genzyme Corporation Clinical Trial for Myozyme-
Alglucosidase alfa: recombinant human alpha glucosidase (rhGAA). 
Clinical trial for children from 6 to 36 months of age at baseline. Two 
children were included in the trial with baseline ages of > 36 months. 
AGLUO 1702 completed enrollment first and then AGLUO 1602 was 
initiated. 
 
8. AGLUO 1602: Genzyme Corporation Clinical Trial for Myozyme-
Alglucosidase alfa: recombinant human alpha glucosidase (rhGAA). 
Clinical trial designed for children from birth to 6 months of age at 
baseline. One child was included in the trial with a baseline age of 7.2 
months. 
 
9.  ERT:  enzyme replacement therapy 
10. GMQ:  The Gross Motor Quotient is derived from the standard scores 
of three gross motor subtests. A total gross motor function standard 
score is determined from norm-referenced data. It measures a child’s 
total gross motor development. A quotient of 80-89 is considered 
“below average” and a 70-79 score “poor”. 
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11. GMC: Gross Motor Composite. Each gross motor subtest raw score is 
transformed into a percentage score. The subtest percentage scores 
are summed and divided by three to create the GMC. 
 
The data set will be described in two manuscripts. 
Gross Motor Development of Children with Pompe Disease with Variable Levels 
of Functional Mobility-Use of the Peabody Developmental Motor Scales- Second 
Edition 
 Aims: 
a) To investigate the responsiveness to change of the PDMS-2 in children 
with Pompe disease who participated in ERT and demonstrated 
clinically meaningful change on the PPEDI and AIMS. 
b) To investigate the responsiveness to change of the PDMS-2 in children 
with Pompe disease who participated in ERT when subjects are 
classified according to level of functional mobility. 
 
Concurrent Validity of the Peabody Developmental Motor Scales- Second Edition 
and the Pediatric Evaluation of Disability Inventory, the Pompe Pediatric 
Evaluation of Disability and the Alberta Infant Motor Scale. 
Aim:  
 To evaluate the concurrent validity of the PDMS-2 and the Pediatric 
 Evaluation of Disability Inventory, the Pompe Pediatric Evaluation of 
 Disability and the Alberta Infant Motor Scale in a sample of infants and 
 children with Pompe disease 
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Chapter II. 
Gross Motor Development of Children with Pompe Disease with Variable Levels 
of Functional Mobility - Use of the Peabody Developmental Motor Scales - 
Second Edition 
Introduction 
 As medical advances continue to increase life expectancy in rare diseases 
such as Pompe disease, valid assessment of developmental motor outcomes is 
necessary to accurately document disease history, evaluate efficacy of the 
intervention, and supplement clinical decision-making. The validity of a tool is not 
an absolute value because it varies according to the purpose of use, and the 
population of subjects tested.1  Test validity should be an ongoing process in 
order to define appropriate use with new populations. When investigators are 
faced with choosing outcome measures, in the absence of a gold standard, test 
selection is limited to the best available measure. They look to tools with good 
psychometric properties for the defined research age group that have been used 
in other diagnoses with similar neuromuscular presentations.  Researchers must 
then continue to evaluate new evidence for application to their clinical 
population.1   
 A motor outcome measure with adequate responsiveness to change has 
not been established for use in infantile Pompe disease.  Pompe disease is a 
rare lysosomal storage disease characterized by a deficiency of the enzyme acid 
alpha glucosidase (GAA).2 Lack of GAA causes accumulation of glycogen in 
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cardiac, skeletal, and smooth muscle and central nervous system tissue, leading 
to progressive cardiomyopathy, respiratory compromise, generalized weakness 
and hypotonia.2 The natural history of infantile onset Pompe disease typically 
leads to death by one year of age.3   Infants treated with recombinant human 
acid α glucosidase (Myozyme) have been shown to have decreased ventilator 
use and decreased risk of death. Developmental motor skill acquisition in 
response to Myozyme has been variable. 
 Motor efficacy was measured in the pivotal Genzyme Corporation, 
Myozyme clinical trials (AGLUO 1602 and AGLUO 1702) with administration of 
the Peabody Developmental Motor Scales- second edition (PDMS-2), the AIberta 
Infant Motor Scale (AIMS), the Pediatric Evaluation of Disability Inventory (PEDI) 
and the Pompe Pediatric Evaluation of Disability Inventory (PPEDI).3 Kishnani et 
al (2007) reported that 13 of 18 children in AGLUO-1602 demonstrated motor 
and functional changes on the AIMS and PPEDI. 3 Nicolino et al (2009) 
documented an “age equivalent motor change score” in AGLUO-1702, but no 
scores or data analyses were included in the manuscript.4   Functional skill 
acquisition varied from the ability to roll and sit independently to walking 
independently.3 No functional outcome data have been published on the PDMS-2 
motor outcomes. 
 According to the manual, possible uses of the PDMS-2 include; 
“determination of motor competency relative to a normative peer sample, 
assessment of qualitative and quantitative capacities of individual gross motor 
and fine motor skills, evaluation of progress over time and determination of 
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efficacy of interventions in research.”5 (page 8) The manual does not indicate 
that the PDMS-2 is most appropriate for specific diagnoses or defined levels of 
functional mobility. The PDMS-2 is widely used in a variety of clinical settings 
including evaluation centers for the Infant Toddler Program,6 preschools and 
schools, therapy centers and specialty clinics. Therefore, current use includes 
children with a very wide range of developmental disabilities and functional 
presentations.7 There is a paucity of evidence to support the validity of use in 
children with chronic disease or significant developmental disability.8   A review 
of the literature identified only one article on the responsiveness of the PDMS-2 
gross motor subtests or composite scores. 
 Responsiveness can be defined as the ability to measure clinically 
important change over time.9 Wang et al (2006) evaluated the responsiveness to 
change of the PDMS-2 in children with cerebral palsy over a three-month period 
using paired t-tests, effect size, standardized response mean and the Guyatt 
Responsiveness Index.9   Subtest raw scores were used to calculate percentage 
scores for the subtests. Subtest percentage scores were then used to calculate 
gross, fine and total motor composite percentage scores.  Paired t-tests 
demonstrated that a statistically significant change (p<. 001) was present from 
baseline to end of study in the gross, fine and total motor percentage scores.  
The effect size for the gross motor subtest percentage score was labeled as 
small at 0.2 according to Cohen standards.9 The standardized response mean 
for the gross motor composite was labeled as trivial at 0.9.  Information was not 
included on individual subtests within gross motor composites.   
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 Responsiveness depends on the number of items on the instrument and 
the standard error of measurement of the instrument.10   The more items on the 
instrument, and the smaller the standard error of measurement, the greater the 
opportunity to detect change.10  Content validity defines the extent to which the 
items reflect a content domain and it is clear that no items are missing.  
According to the PDMS-2 manual the Stationary content measures “the child’s 
ability to sustain control of his or her body within its center of gravity and retain 
equilibrium.” 4 (page 34) The Stationary subtest may have reduced content 
validity and reduced responsiveness due to a lack of inclusion of items to 
measure standing balance. The Stationary items progress from maintaining 
balance in kneeling for five seconds to standing on one foot independently with 
no items available to qualitatively analyze stationary standing or transitions in 
and out of standing. Only one item is included with an age representation 
between 13 and 31 months. Instrument precision can be decreased if large 
jumps in activity level are required to gain item credit. Children who do not pass 
the next item may have ability close to the item passed or close to the failed item 
but the true level cannot be determined.11 The Stationary subtest item gaps may 
lead to decreased test responsiveness in children who have difficulty with 
standing balance, have delayed acquisition of independent walking, or require 
use of adaptive equipment or caregiver assistance to maintain standing or to 
ambulate. 
 The PDMS-2 test developers report content validity with mean item 
discrimination coefficients in each subscale.5 In the Stationary subscale the 
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lowest discrimination coefficient, r=. 41 was found with children in the normative 
sample in the 36-47 month age group. Item #20, standing on one foot for 3 
seconds is the recommended administration starting place for children 27-38 
months of age.  
 Stationary subtest item gaps may lead to misinterpretation of intervention 
efficacy and inaccurate age equivalent and standard score representation.   
Gross motor subtest raw scores are converted to subtest standard scores and 
combined to form the Gross Motor Quotient (GMQ). Test developers recommend 
the most credence be given to the motor quotient scores when important 
decisions are to be made about diagnosis or placement.5 All standard scores are 
calculated based on the number of credited items in the normative sample. A 
Stationary subtest raw score that has reached a plateau could present as a lower 
standard score at subsequent testing, and result in a lower and possibly 
inaccurate GMQ.  
 Research supports that the psychometric properties on the PDMS-2 are 
poorer for the Stationary than the Locomotion subtest. In examining the 
concurrent validity of the PDMS-2 with the AIMS and the Bayley Scales of Infant 
Development-II (BSID-II), the largest subtest coefficient correlations were found 
with the Locomotion subtest.12-14 Snyder et al (2008) examined the concurrent 
validity of the AIMS and the PDMS 2 gross motor subtests in infants at risk for 
motor delay from birth to eighteen months of age.12 The Pearson product 
moment correlations varied from r= .78 to. 97.  The largest correlation coefficient 
of r=. 97 was found for the Locomotion subtest in infants less than nine months of 
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age.  Concurrent validity has also been evaluated between the PDMS-2 and the 
BSID-II in typically developing, twelve month old infants.14 The standard scores 
on the PDMS-2 GMQ and the BSID-II Motor Scale showed a low and non-
significant correlation value of r=. 30.  No correlation was found between the age 
equivalent scores for the Stationary and Object Manipulation subtests and the 
BSID-II, but a high and significant correlation (r=. 71 p<. 05) was found between 
the age equivalent PDMS-2 Locomotion subtest and the BSID-II.  
Purpose 
 The purpose of this study was to examine the responsiveness of the PDMS-
2 in an investigation of intervention efficacy for children diagnosed with Pompe 
disease. Secondary analyses of the PDMS-2 data, from the Genzyme 
Corporation, Myozyme, enzyme replacement therapy (ERT) clinical trials were 
completed. The responsiveness to change on the PDMS-2 individual gross motor 
subtests was examined in children who had been diagnosed with Pompe disease 
and who demonstrated clinically meaningful change on the AIMS and PPEDI. A 
second purpose was to compare responsiveness to change in two groups of 
children diagnosed with Pompe disease who had different levels of functional 
mobility.    
Research Questions 
1. Are the PDMS-2 gross motor subtests and gross motor composite score 
responsive to gross motor change over a 52-week period in children 
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diagnosed with Pompe disease who demonstrated clinically meaningful 
change on the AIMS and PPEDI? 
2. Are the PDMS-2 gross motor subtests and gross motor composite score 
more responsive to change in motor function in children diagnosed with 
Pompe disease who ambulate without assistive devices, as compared to 
children who ambulate with an assistive device or who are unable to 
ambulate?  
 It was hypothesized that the Stationary subtest would be less responsive 
than the Locomotion or Object Manipulation subtest. Lack of responsiveness was 
expected to be most problematic for children with decreased dynamic standing 
balance and delayed acquisition of independent walking. These data analyses 
may help to inform clinical decision making for children with Pompe disease and 
design of future clinical trials. The children in these data sets are diverse in age 
and functional presentation. The functional presentations are similar to many 
children who are typically followed in pediatric clinics. Identification of PDMS-2 
strengths and limitations for use may be clinically applicable for a larger range of 
developmental disabilities. 
Participants 
 Fourteen of the 34 children from AGLUO-1602 and 1702 data were 
included in the analyses. Twenty-three of the 34 children had clinically significant 
change on the PPEDI Functional Skills Mobility dimension and improvements in 
the total AIMS score at the one-year follow-up.  Nine of the 23 were excluded for 
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the following reasons; six subjects did not have complete PDMS-2 data for the 
testing time frames, two children had a cross reactive immunologic negative 
status (CRIM-) and one patient showed improvement initially and then showed 
decline at the final assessment. Total absence of GAA is described as CRIM – 
and Myozyme ERT has been shown to be less effective in CRIM- patients.3  
 A level of clinically meaningful change for the AIMS and the PPEDI has 
not been established in children diagnosed with Pompe disease.  Minimal 
detectable change has been described as the amount of change that exceeds 
the standard error of the instrument.10 The test developers for the PEDI and 
PPEDI recommend use of the standard error in interpretation, and state that 
change that exceeds 2x the standard error represents improved functional 
performance.15  Clinically meaningful change for this study was defined as 
change scores that exceeded 2x the standard error.  
Functional Classification 
 The FDA submission for Myozyme market approval and manuscripts 
summarizing the clinical trials have classified responders as independent 
walkers, standers/walkers with assistance and independent sitters who were 
unable to sustain weight bearing in standing.4, 16 Similarly, the children in this 
analysis were divided into three groups according to level of functional mobility.  
The AIMS scores at one year follow-up determined functional group placement. 
Group one included children who could transition in and out of 
standing without adult assistance and walk without an assistive 
device if they were older than two years of age. If they were 18 
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months to two years of age they were able to cruise independently 
at furniture and stand momentarily without assistance. Inclusion 
was determined by an AIMS standing score of 13 or more for 
children at least two years of age and an AIMS standing score of 10 
or more for children younger than two years of age.  Six children 
were classified as group one. 
Group two included children who sat independently and were able 
to quadruped crawl. They were able to take weight into their legs 
and stand or walk with use of assistive devices or caregiver.  An 
AIMS standing score of 3-9, AIMS sitting score of 10 or greater and 
a prone score of 17 or greater determined inclusion. Only one child 
was classified as group two. 
  Group three included children who were able to sit independently.   
  If mobility was present, it was through belly crawling or wheelchair  
  propulsion. Inclusion was determined by AIMS sitting score of less  
  than 10.  Seven children were classified as group three. 
 Group two and three were combined to form one functional group for data 
analyses because only one subject was classified as group two.  The combined 
group was labeled as group two and included all children who did not 
demonstrate the ability to walk or cruise independently. 
 Table 1 includes a gender and age distribution by functional classification. 
Group two had an older group mean age (21.5 months) than group one (15 
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months).  Group two included a 37- and a 43-month-old child who fell outside of 
the original clinical trial protocol inclusion criteria of 36 months. Functional 
presentation in Pompe disease is not assumed to improve linearly by age.  The 
older subjects in group two did not have the lowest or highest function in the 
group when subjects were ranked from lowest to highest function with Gross 
Motor Composite (GMC) percentage scores. Subject A ranked 3/8 and subject B 
ranked 5/8. The ranking indicates that although they were the oldest they did not 
have the lowest or highest functional skills in group two.  Table 2 displays the 
older children’s individual subtest percentage scores and the mean group two 
subtest scores.  
Procedure 
 The AGLUO-1602 and 1702 data were collected by physical therapists in 
the USA, Taiwan, Europe and Israel. The primary author of this manuscript 
collected USA clinical data and assisted with international reliability training. 
Reliability training included a review of the theoretical basis for each assessment, 
instruction on administration guidelines and data reporting and establishing inter-
rater reliability of 90% agreement for all of the tests.  To minimize investigator 
bias, the assessors did not review previous scores prior to administration of a 
repeat assessment. The same therapist at each site administered all repeat 
assessments. Following administration of the assessment score sheets were 
forwarded to central scoring and entered into a database.  
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 The secondary analyses first included identification of children who 
demonstrated clinically meaningful change scores. Then the identified children 
were classified into functional group one and two for statistical analyses. 
PDMS-2  
 The PDMS-2 is a standardized norm referenced test for children from birth 
to 72 months of age. 5 Four subtests make up the gross motor composite, 
Reflexes, Stationary, Locomotion and Object Manipulation.  All items are scored 
on a three point scale with 0 indicating that the criteria for successful 
performance were not met, 1 indicating the behavior is emerging and a 2 
indicating successful performance of the item criteria. 5   The PDMS-2 raw 
subtest scores typically are used to calculate standard percentile and age 
equivalent scores. The gross motor subtest standard scores are used to 
calculate the overall Gross Motor Quotient. The Reflex subtest is indicated only 
for subjects less than one year of age, and Object Manipulation subtest is used 
only after 12 months of age.  PDMS-2 standard subtest scores and motor 
quotients are calculated using normative age data.  They are beneficial for 
identifying risk and level of developmental delay but are not suitable for use in 
determining responsiveness.9   Subtest raw score comparisons cannot be made 
because the subtests all contain a different number of test items. Similar to 
PDMS-2 responsiveness work completed by Wang et al, (2006), each subtest 
raw score was transformed into a percentage score.9   The percentage score was 
calculated by dividing the obtained raw score by the maximum raw score and 
multiplying by 100.9    
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 The PDMS-2 was administered according to the guidelines in the manual. 
The Stationary, Locomotion and Object Manipulation subtest percentage scores 
were used to calculate the Gross Motor Composite (GMC) score because all 
participants were greater than one year of age at the established baseline entry 
period. The original protocol specified that the PDMS-2 would be completed at 
study initiation, the first assessment after one year of age, and then every 3 
months until study completion. The first assessment period after one year of age 
was defined as baseline for this analysis, and the second assessment was 52 
weeks after the established baseline.  The protocol allowed a +/- 7day window for 
assessment administration. A baseline entry of at least 12 months of age allowed 
subjects to be analyzed on the same three subtests, Stationary, Locomotion and 
Object Manipulation. It also allowed the same three subtests to be used to 
calculate the GMC percentage scores.  An entry assessment age of at least 12 
months also captures the developmental time frame in which standing stationary 
and transition skills are expected to begin emerging. Use of this time frame was 
essential to evaluate the responsiveness concerns in the Stationary subtest.  
Data Analysis 
 Descriptive statistics were calculated for the group as a whole and for 
children in each of the functional groups (Table 1). Responsiveness to change in 
the individual subtests and the GMC in the whole group was calculated with four 
one way repeated measure ANOVAs. Subtest and GMC responsiveness by 
function was calculated with four two way repeated measure ANOVAs. Each 
ANOVA had two factors, time (within group at baseline and week 52) and 
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functional classification (between group one and two). A SAS general linear 
model framework was used for all ANOVAs. A Tukey–Kramer correction factor 
was used to adjust for multiple comparisons at an a priori significance level of 
0.05. 
 Two response indices were calculated, Effect Size (ES) and Standardized 
Response Mean (SRM).  ES is the measure of change obtained by dividing the 
mean change from baseline to week 52 by the pooled standard deviation of 
baseline and week 52. Absolute standards for interpretation of ES are not 
available. The values of the ES were interpreted according to Cohen 
recommendations as trivial (ES of <0.2), small (ES of >=0.2 <0.5), moderate (ES 
of >=0.5<0.8), or large (ES of >=0.8) A small effect size is 20% of one standard 
deviation.9 SRM provides an estimate of change in the measure, standardized 
relative to between-subject variability in change scores.9 SRM is ES adjusted for 
the value of the correlation coefficient between the baseline and week 52 mean 
values.17 Cohen standards were used for interpretation.9  
Results 
 Summary results are presented in Table 3 for the whole group with 
functional groups one and two combined. Repeated measure ANOVAs 
documented that a significant difference was present between the mean subtest 
percentage values at baseline and at week 52. The ES and SRM were moderate 
for the Locomotion subtest and large for the Object Manipulation and Stationary 
subtests and the GMC.  
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 Table 4 outlines individual subtest and GMC responsiveness by the 
factors of Time and Function. Although an interaction effect was found in the 
Object Manipulation subtest, it was not relevant to the research questions in this 
manuscript. The test for simple main effects for Time and Function found a 
significant difference in the mean percentage scores for all three subtests and for  
the GMC.  
Locomotion 
 Table 5 outlines the post hoc analysis and the response indices for the 
Locomotion subtest. A significant difference was present in the mean percentage 
scores from baseline to week 52 for both functional groups.  A significant 
difference between the two functional groups was not present at baseline, but 
was present at week 52. The ES and SRM values were large for functional group 
one and moderate for functional group two.  
Object Manipulation 
 Table 6 outlines the post hoc analysis and the response indices for the 
Object Manipulation subtest.  A significant difference was present in the mean 
percentage scores from baseline to week 52 for functional group one only. A 
significant difference between functional group one and two was not present at 
baseline, but was present at week 52. The ES and SRM values were large for 
functional group one and small for functional group two.   
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Stationary 
 Table 7 outlines the post hoc analysis and the response indices for the 
Stationary subtest. No significant difference was present between baseline and 
week 52 mean percentage scores for either functional group. In addition, no 
significant differences were present between groups at either time point. The ES 
and SRM values were large for both functional groups. 
GMC 
 Table 8 outlines the post hoc analysis and the response indices for the 
GMC. A significant difference was present between baseline and week 52 mean 
percentage scores for both functional groups.  No significant differences between 
groups were present at either time point. The ES and SRM values were large for 
functional group one and moderate for functional group two.  
Discussion 
 The results of this study support adequate responsiveness of the PDMS-2 
percentage GMC scores in a heterogeneous group of children with Pompe 
disease. Wang et al (2006) also documented acceptable responsiveness of the 
composite scores of the PDMS-2 in children with cerebral palsy with a wide 
range of functional abilities.9   However, Wang did not measure responsiveness 
separately for varied functional presentations and for each separate subtest.9 
The mean GMC percentage scores were significantly different from baseline to 
week 52 in both functional groups.  The large Locomotion subtest mean 
percentage change score in group two could have influenced the overall GMC 
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percentage change score because a significant difference was not found in the 
other two subtests. The PDMS-2 manual recommends the GMC as the best 
estimator of gross motor competency, and the composite score is derived from 
all three subtests. 4  
 Although the testing time frame for this research was 52 weeks, clinical 
reevaluations for reauthorization of therapy services often need to be completed 
every three to six months. Over this shorter time frame, a smaller change in 
Locomotion subtest score may be present. A smaller Locomotion subtest change 
score, paired with the same lack of change on the other two subtests, may not 
produce a significantly different mean GMC change score. 
 “Responsive measures discriminate between trivial and substantial 
change within groups and differentiate between those groups.” 17(page 3) The 
Locomotion subtest was able to discriminate change within both groups from 
baseline to week 52 and between groups at both time periods. The Stationary 
subtest was unable to discriminate within group or between group differences. 
The Object Manipulation subtest discriminated change within group one from 
baseline to week 52 and between the functional presentations of group one and 
group two at week 52. The Locomotion subtest measures the child’s ability to 
move his or her body from one base of support to another and includes not only 
ambulation, but rolling, pivot in sitting, and crawling.4 Although functional group 
one and two had different levels of functional locomotion, the Locomotion subtest 
was responsive to change in both groups. An essential component of Locomotion 
is balance.  The Stationary subtest measures balance and is defined in the 
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manual as “the ability to sustain body control within the center of gravity and 
retain equilibrium.” 4 (page 34)  Gross motor skill acquisition should be evident 
not only in the Locomotion subtest but paired to some extent with change in the 
Stationary and Object Manipulation subtests. Items are present on the Stationary 
subtest to capture balance in sitting, but no items are present to quantify quality 
of bipedal standing balance or transitions in and out of standing. Table 9 shows 
an example of PDMS-2 scores for two subjects, one from each functional group.  
The children had stationary subtest raw scores that were very similar (38, 36), 
but Locomotion subtest raw scores that were very different (113, 44). The 
Locomotion raw subtest scores equate to very different functional presentations. 
Subject A was able to ambulate independently and walk up stairs, and had 
emerging jumping skills. Subject B could sit independently, pivot in sitting, and 
creep on hands and knees. The Stationary subtest scores do not differentiate 
between the children’s different levels of balance.  
 Responsiveness and content validity are dependent on an adequate 
number of test items to capture the content domain and measure meaningful 
change. Thirteen out of fourteen children had a Stationary subtest week 52 raw 
score between 36 and 38.  This represents a ceiling effect prior to either item 
#19, maintaining balance in tall kneeling or item #20 standing on one foot for 3 
seconds.  
 The Object Manipulation subtest was responsive to change within group 
one for children who have the ability to stand independently and throw or kick a 
ball Children with a greater degree of developmental disability with an inability to 
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maintain independent standing could not progress on the Object Manipulation 
items (functional group two).  Item #1 and #2 require only independent sitting 
balance to catch and roll a ball. But item #3 requires independent standing to 
fling a ball. The children in functional group two were limited in their ability to 
successfully complete items beyond #2. Five of the eight children in functional 
group two had a final score on the Object Manipulation subtest of 4 or less. Poor 
responsiveness to change in functional group two was supported with a non-
significant ANOVA value and a small SRM of .47. The Object Manipulation 
subtest for functional group one had a large effect with a SRM of 3.8.  
 Response indices values indicate that the Locomotion and the GMC were 
also more responsive to change in functional group one than group two.  Values 
were in the large range for functional group one and in the moderate range for 
functional group two. The ES is calculated by dividing the mean change score by 
the pooled standard deviation of the baseline and week 52 scores. Functional 
group one had a larger mean change score and less variance in scores than 
functional group two, thus creating larger response indices. The Stationary 
subtest ES and SRM values were large in both functional groups and did not 
support the lack of responsiveness to change found in the post hoc p-values. 
Effect size is affected by group variance. The Stationary subtest had a very small 
score variance, thus creating a large effect size. Therefore the ES and SRM 
should be interpreted with caution because the lack of items to capture standing 
function actually created a large ES.  
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Application to Clinical Practice and use in Research 
 Although the results of this research are directly applicable only to children 
with a diagnosis of Pompe disease, the identified limitations of use may be 
appropriate to consider with other diagnoses. The functional distribution of the 
sample was not dissimilar to what might be seen in typical pediatric clinic 
environments. Children with other diagnoses can present similar to functional 
group one with generalized weakness, delayed acquisition of independent 
ambulation and challenges with high balance and coordination skills or similar to 
functional group two with the ability to sit independently, required use of adaptive 
equipment to ambulate or stand, and primary community mobility with a 
wheelchair. Therapists and physicians should exercise caution in interpretation of 
the Stationary subtest as a valid evaluative measure of change.  Similarly, the 
Object Manipulation subtest may not measure change in function for children 
with limited ability to maintain independent standing. Inclusion of subtest scores 
on reports should be paired with a detailed qualitative description of functional 
presentation and areas of noted decline or improvement. The Locomotion 
subtest may be the most useful test for evaluative measurement in clinical and 
research protocols. 
 Conversion of subtest raw scores into percentage scores may be 
beneficial for interpretation as an evaluative measure. Norm referenced standard 
scores are appropriate for use as a discriminative tool but very challenging to 
interpret as an evaluative measure of change.   Accurate standard score 
interpretation by health care and school professionals, insurance agencies and 
 48 
parents is essential to guide decision making and plan of care development. 
Professionals and parents may be unaware that the same standard score on two 
consecutive testing periods actually represents motor skill acquisition. The raw 
scores in this research were easily converted into percentage scores.  PDMS-2 
percentage score use as a measurement of change in performance would be 
very similar to the percentage scores on the GMFM 88 or the scaled scores on 
the PEDI.15,18 
 This research highlighted the importance of functional classification of 
subjects in Pompe disease efficacy research.  Ongoing development of a more 
detailed functional classification system for use in Pompe disease is 
recommended. The PDMS-2 may be most appropriately used in children with 
mild developmental delay, who have the capacity or potential to; balance in 
standing to complete ball skills and acquire higher standing skills like standing on 
one foot. Use of the Locomotion subtest as a discriminative measure to define 
function relative to a normative sample may also be appropriate.  A wide 
heterogeneity is present in the functional presentation of children with Pompe 
disease, and functional course is not always predictable. For a study sample that 
includes a majority of children with significant motor impairment, the Stationary 
and Object Manipulation subtests may not have adequate responsiveness to 
change.  
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Limitations 
 Despite the sample size, this study did serve to identify some potential 
areas of concern with the use of the PDMS-2 gross motor scales in children with 
Pompe disease.  Pompe disease is an extremely rare condition, and recruitment 
was limited to a convenience sample. Sample sizes for the secondary analyses 
were also limited due to incomplete data at some assessment periods.  
Conclusion 
 The PDMS-2 manual provides no guidelines for interpretation of standard 
scores as evaluative measures. Conversion of PDMS-2 subtest raw scores into 
percentage scores supported increased utility as an evaluative measure.  
 The PDMS-2 gross motor subtests and GMC percentage scores were 
responsive to change in a heterogeneous group of children with Pompe disease.  
Responsiveness concerns were identified in the Object Manipulation and 
Stationary subtest when the children were divided into two different functional 
groups. Level of functional mobility should be taken into consideration when 
evaluating PDMS-2 use for future Pompe disease research.  
 The Locomotion subtest may be the most useful PDMS-2 gross motor 
subtest for evaluative measurement of clinical change in Pompe disease. The 
Locomotion subtest had adequate within-group responsiveness over time and 
was able to discriminate between the two groups at week 52. The 
Responsiveness to change results on the Stationary subtest were inconsistent 
between the post hoc analyses and the response indices. Additional study is 
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justified to explore the clinical and research utility of the PDMS-2 in this 
population.   
 
 
Table 1.  
Gender and Age Distribution by Functional Classification 
Function n Gender 
Mean Age at 
Baseline in       
months SD Min Max 
Group One 6 4 M, 2 F 15.0 2.5 12 19 
Group Two 8 5 M, 3 F 21.5 11.1 12 43 
Total 14 9 M, 5 F 18.9 9.0 12 43 
 
 
Table 2. 
PDMS-2a Percentage Scores for Older Subjects in Functional Group Two 
Subjects Stationary  Locomotion  OMb  
A. 37 months of age 53 5 0 
B. 43 months of age 60 25 8 
Functional Group Two 
Mean Percentage Scores 50.2(12.4) 20.8(18.1) 9.6(12.3) 
a PDMS-2: Peabody Developmental Motor Scales- 2nd edition  
b OM - Object Manipulation 
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Table 3. 
Responsiveness of PDMS-2a Individual Subtest and GMCb Percentage 
Scores from Baseline to Week 52; Functional Group One and Two 
Combined 
 
Baseline 
Mean (SD) 
Week 52 
Mean (SD) F value (p) ESc SRMc 
Locomotion 30.2(17.4) 42.6(19.1) 26.71(<.0001)* 0.68 0.58 
OMd 13.0(11.2) 31.3(21.5) 22.86(.0004)* 1.07 1.05 
Stationary 56.2(8.3) 62.3(4.2) 8.71(.011)* 0.92 0.87 
GMCb 34.2(11.3) 46.7(13.9) 38.02(<.0001)* .98 0.94 
a PDMS-2: Peabody Developmental Motor Scales- 2nd edition  
b GMC-Gross Motor Composite 
c Cohen’s d used for Effect Size (ES)and Standardized Response Mean(SRM); trivial <0.2, small 
=0.2 <0.5, moderate >=0.5<0.8,large >=0.8 
d OM - Object Manipulation 
 
 
Table 4.  
ANOVA Results for PDMS-2a Individual Subtests and GMCb Percentage 
Scores Factors:  
Effect Locomotion OMc Stationary GMCb 
  F value (p) F value (p) F value (p) F value (p) 
Time  31.97(.0001)* 72.04(<.0001)* 10.13(.008)* 4.75(<.001)* 
Function 10.74(.0066)* 7.06(.021)* 6.34(.027)* 4.33(.059) 
Time*Function 2.61(.1320) 23.30(.0004)* .31(.590) 2.85(.117) 
a PDMS-2: Peabody Developmental Motor Scales- 2nd edition  
b GMC-Gross Motor Composite 
c OM-Object Manipulation 
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Table 5. 
Results of Post Hoc Analysis of Locomotion Subtest by Time and 
Functiona, with Responsiveness Indices 
Subtest Function  
Baseline 
Mean 
Percentage 
(SD)  
Week 52  
Mean 
Percentage 
(SD)  
t value 
(adj. p) ESb  SRMb  
Locomotion 1 41.7(9.6) 58.2(6.5) 5.36(.0009)* 2.02 2.66 
Locomotion 2 20.8(18.1) 32.9(14.0) 4.51(.003)* 0.75 0.66 
t value  
(adj. p)   2.88(.059) 3.49(.02)*       
a Post Hoc analyses with Tukey-Kramer test for multiple comparisons 
b Cohen’s d used for Effect Size(ES) and Standardized Response Mean(SRM); trivial <0.2, small 
=0.2 <0.5, moderate >=0.5<0.8,large >=0.8 
 
 
Table 6. 
Results of Post Hoc Analysis of Object Manipulation (OM) Subtest by Time 
and Functiona, with Responsiveness Indices 
Subtest 
Functio
n  
Baseline  
Mean 
Percentage 
(SD)  
Week 52  
Mean 
Percentage 
(SD)  
t value 
(adj. p) ESb SRMb  
OM 1 17.0(9.2) 48.3(14.9) 8.81(<.0001)* 2.53 3.80 
OM 2 9.6(12.3) 18.0(16.8) 2.80(.067) 0.57 0.47 
t value  
(adj p)   97(.768) 4.10(.007)*       
aPost Hoc analyses with Tukey-Kramer test for multiple comparisons 
b Cohen’s d used for Effect Size(ES) and Standardized Response Mean(SRM); trivial <0.2, small 
=0.2 <0.5, moderate >=0.5<0.8,large >=0.8 
 
 
 
 
 
 
 
 53 
Table 7. 
Results of Post Hoc Analysis of Stationary Subtest by Time and Functiona, 
with Responsiveness Indices 
Subtest 
Functio
n  
Baseline 
Mean 
Percentage 
(SD) 
Week 52  
Mean 
Percentage 
(SD)  
t value 
(adj. p) ESb (d) SRM b 
Stationary 1 60.6(1.7) 65.3(3.7) 1.46(.488) 1.63 1.91 
Stationary 2 50.2(12.4) 60.0(3.1) 2.53(.105) 1.08 1.06 
t value  
(adj. p)   2.41(.128) 1.66(.382)       
a Post Hoc analyses with Tukey-Kramer test for multiple comparisons 
b Cohen’s d used for Effect Size(ES) and Standardized Response Mean(SRM); trivial <0.2, small 
=0.2 <0.5, moderate >=0.5<0.8,large >=0.8 
 
 
Table 8. 
Results of Post Hoc Analysis of Gross Motor Composite by Time and 
Function a, with Responsiveness Indices 
 
Composite 
Functio
n  
Baseline 
Mean 
Percentage 
(SD) 
Week 52  
Mean 
Percentage 
(SD) 
t value   
(adj. p) ESb (d) SRM b  
Gross 
Motor  1 39.3(6.1) 55.4(8.5) 5.59(.0001)* 2.17 1.06 
Gross 
Motor 2 30.4(13.1) 40.1(13.9) 3.38(.027)* 0.72 0.63 
t value  
(adj. p)   1.45(.4928) 2.50(.11)       
a Post Hoc analyses with Tukey-Kramer test for multiple comparisons 
b Cohen’s d used for Effect Size(ES) and Standardized Response Mean(SRM); trivial <0.2, small 
=0.2 <0.5, moderate >=0.5<0.8,large >=0.8 
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Table 9. 
Example of PDMS-2a Raw Scores at Baseline and Week 52 for Two Subjects 
 
  Time 
Subject A  
Functional 
Group One 
Subject B  
Functional 
Group Two 
Age at 
Baseline  12m 15m 
Stationary Baseline 36 32 
  Week 52 38 36 
OMb Baseline 4 2 
  Week 52 19 4 
Locomotion Baseline 68 34 
  Week 52 113 44 
a PDMS-2: Peabody Developmental Motor Scales- 2nd edition  
bOM-Object Manipulation 
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Chapter III.  
Concurrent Validity of the Peabody Developmental Motor Scales - Second 
Edition and the Pediatric Evaluation of Disability Inventory, the Pompe Pediatric 
Evaluation of Disability, and the Alberta Infant Motor Scale in Children with 
Pompe Disease 
Introduction 
 Documentation of eligibility for therapy service and efficacy of intervention 
with standardized, norm-referenced assessment tools is increasingly being 
required for reimbursement.  Eligibility for the North Carolina Infant Toddler 
Program currently requires children to have an established condition or 
developmental delay documented with scores of 2.0 standard deviations below 
the mean on standardized tests or 30% delay on an instrument which uses age 
equivalent test scores.1 The Guide to Physical Therapy Practice includes tests 
and measurements as an essential component in examination and evaluation, 
used to establish functional limitations, impairments and baseline information.2 
Pediatric physical therapists are completing standardized assessments as part of 
their routine clinical practice, with 59% reporting that they use a standardized 
measure daily or weekly.3  
 In a survey of pediatric physical therapists, the Gross Motor Function 
Measure 88 (GMFM), the Alberta Infant Motor Scale (AIMS) and the Peabody 
Developmental Motor Scales-2 (PDMS-2) were the three most commonly used 
pediatric motor outcome measurement tools.3 The GMFM - 88 is a criterion 
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based assessment tool that does not provide a comparison to a normative 
sample.   The PDMS-2 and the AIMS are both evaluative measures designed to 
assess motor development and provide normative percentile ranking and age 
equivalent scores.4 The PDMS-2 is appropriate for use from birth to 72 months of 
age and the AIMS from birth to 18 months of age.5  
 Test selection, to determine eligibility for services, may vary regionally, 
and specific tests may be mandated for use at a county or state level. Therapists 
must have an awareness of test limitations and strengths and to what degree the 
scores are related to scores on other standardized tests. Lack of agreement 
between outcome measurement scores may change eligibility status for services 
between agencies and geographic regions and misinform efficacy intervention 
research. Concurrent validity is one method of evaluating the level of agreement 
that is present between two outcome measurements. The validity of tool use for a 
specific population is demonstrated if a strong relationship is established 
between the tool and a criterion reference tool.  
 PDMS-2 test developers evaluated concurrent validity between the 
PDMS-2 and the Mullen Scales of Early Learning (MSEL) in typically developing 
children. The MSEL provides a baseline measurement of cognition and motor 
development. The largest correlation coefficients were present between the 
MSEL and the PDMS-2 Gross Motor Quotient (r=. 86.) and between the MSEL 
and Locomotion and Object Manipulation subtests (both r=. 90).4 The PDMS-2 
Stationary subtest did not correlate significantly with the MSEL Gross Motor 
Scale.  
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 Snyder et al (2008) examined the concurrent validity of the AIMS and the 
PDMS-2 gross motor subtests on infants at risk for motor delay from birth to 18 
months of age.6 The Pearson product moment correlations varied from r= .78 to 
.97. The largest correlation coefficient of r=. 97 was found for the Locomotion 
subtest in infants less than nine months of age.  
 Researchers have found that the Bayley Scales of Infant Development II 
(BSID-II) Psychomotor Index (PDI) and the PDMS-2 had the strongest 
concurrent agreement for the Locomotion subtest, and that inconsistency was 
present in the ability to determine significant delay with standard scores.7,8 The 
BSID-II – PDI is a discriminative motor scale that is used to identify 
developmental delay in children from one month to 3.5 years of age. Provost et al 
(2004) found that more than 75% of the sample classified as significantly delayed 
on the BSID-II (PDI <=69) did not score in the classification of “very poor” (TMQ, 
=69) on the PDMS-2. 7 The PDMS-2 Locomotion subtest showed a high age 
equivalent correlation of r=. 97 with the BSID-II PDI.   The Locomotion subtest 
also showed the highest age equivalent agreement with the BSID PDI at 96% 
within 3 months.  The Stationary and Object Manipulation subtests had only a 90-
95% agreement within five months.  
 Connolly et al (2006) also examined PDMS-2 concurrent validity and 
found a low (r=. 30) correlation between the standard scores on the PDMS-2 and 
the BSID-II in typically developing, 12 month old infants.8 No correlation was 
found between the age equivalent scores for the Stationary and Object 
Manipulation subtests, but a high and significant correlation (r=. 71, p<. 05) was 
 60 
found between the age equivalent PDMS-2 Locomotion and the BSID-II motor 
scale.8 Lack of agreement between the two tests could represent variability in 
service eligibility.7 When tests are important for clinical decision-making and 
service eligibility, Provost recommends a very high level of correlation (r=. 95) 
between two tests that are used to qualify for services.7 
 PDMS-2 developers reported lower mean item discrimination coefficients 
for the Stationary subtest than the Locomotion subtest.4  Item discrimination, as it 
relates to the PDMS-2, evaluates the subtest’s ability to discriminate between 
different levels of function. The Stationary subtest includes items to capture 
balance in sitting and kneeling, but no items are included to capture standing 
balance or transitions in and out of standing.  The items progress from #19 
maintaining balance in kneeling for five seconds, to #20 standing on one foot for 
three seconds. Each item in the PDMS-2 has a normative age equivalence score 
recorded in months. The age equivalence score for #19 is 13 months and for 
item #20 is 31-32 months. Therefore only one item is included with an age 
representation between 13 and 31 months.  In contrast to the Stationary subtest, 
the AIMS provides five items that qualitatively analyze stationary standing.5 
Large jumps in the activity level required to pass items decrease instrument 
precision.   Item gaps may produce inaccurate age equivalent and standard 
score representation and low concurrent validity values when comparisons are 
made to other pediatric motor outcome measurement tools. 
 Mayrand et al (2009) 9 examined the association between the PDMS-2 
gross motor scale and the Pediatric Evaluation of Disability Inventory (PEDI) 
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Functional Skills Mobility domain in children with language impairment. The PEDI 
is a standardized instrument for children aged 6 months to 7.5 years that uses 
parent report to measure level of disability in self care, mobility and social 
function domains.10 The Functional Skills mobility domain contains items that are 
relevant for daily independence in mobility function such as toilet, chair, 
wheelchair, bed tub and car transfers; bed mobility; indoor and outdoor mobility, 
and stair ascent and descent. The study found a low, non-significant correlation 
(r=. 23) between the PEDI mobility and PDMS-2 GMQ when used with children 
with combined primary language impairment and mild motor impairment. 9 The 
PDMS-2 is a motor outcome measure, whereas the PEDI focuses on the degree 
impairment impacts function in activities of daily living. Although motor capacity 
should reflect actual performance in ADL, the PEDI may not have adequate 
sensitivity to detect subtle motor impairment in children with a primary language 
impairment.9  Better agreement between the PDMS-2 and the PEDI might have 
been present in a population of children with more significant motor impairment.  
 Available research on the concurrent validity of the PDMS-2 focuses on 
typical development and children at risk for developmental delay. There is a 
paucity of evidence to illustrate the relationship between the PDMS-2 and other 
developmental outcome tools in children with chronic disease and moderate 
motor functional impairment. 
 
 
 62 
Pompe Disease   
 Pompe disease is a rare lysosomal storage disease characterized by a 
deficiency of the enzyme acid alpha glucosidase (GAA).11   Lack of GAA causes 
accumulation of glycogen in cardiac, skeletal, and smooth muscle and central 
nervous system tissue, leading to progressive cardiomyopathy, respiratory 
compromise, generalized weakness and hypotonia.11 The natural history of 
infantile onset Pompe disease typically leads to death by 1 year of age.12   Infants 
treated with ERT, in the form of recombinant human acid α glucosidase 
(Myozyme) have been shown to have decreased ventilatory use and decreased 
risk of death. 12 Developmental motor skill acquisition in response to Myozyme 
has been variable. Motor functional classification in response to Myzoyme varies 
from independent ambulators, to functional sitters, to children that require 
caregiver assistance to complete all activities of daily living.12 Functional 
outcomes were measured in the pivotal Genzyme Corporation clinical trials for 
Myozyme (AGLUO 1602 and 1702) with concurrent administration of the PDMS-
2, AIMS, PEDI and the Pompe Pediatric Evaluation of Disability Inventory 
(PPEDI).  
 The Pompe PEDI is a disease specific version of the PEDI that was 
developed to assess functional capabilities and performance in children with 
Pompe disease from 2 months of age through adolescence.  Haley et al (2003) 
modified the original PEDI in 2003 in order to more accurately define the levels of 
physical functioning and disability that were present in children with Pompe 
disease.10  The PPEDI includes all of the items listed in the PEDI, as well as 
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additional items that are designed to reflect clinically relevant skills for children 
with Pompe disease. Items were added to the Functional Skills and Caregiver 
Mobility and Self Care scales to reflect the functional skills and deficits that were 
seen clinically in Pompe disease.10 Fifty-nine items were added to the mobility 
domain and 17 new items were added to the self-care domains. The items were 
added to raise the ceiling, lower the floor, and increase evaluation of assistive 
technology and adaptive equipment and to improve precision of scoring and 
potential sensitivity to change. Norm-based scoring was developed for these new 
items. Scoring algorithms for the PEDI were adjusted to reflect the new 
normative data for the Pompe PEDI. 
 Reliability and validity testing of the PPEDI was completed through 
telephone administration to 30 parents of children with Pompe disease.10 
Subjects were identified on the Glycogen Storage Disease Network (GSD) list 
serve. Study participants were between six months and 22 years of age, primarily 
male (76%) and Caucasian (86%) and lived in the USA, Canada, Germany, 
Spain, and England, but the majority were from the USA. Only 10 of the 30 
children had some ability to ambulate, and all children presented with functional 
skills below age expected normative values. Test re-test was done in a two week 
interval with a mobility domain intra class correlation coefficient of r= .98. Authors 
justified use of a separate assessment for mobility and self-care in Pompe 
disease due to the heterogeneous clinical functional presentation found in 
Pompe disease and the challenges of classifying the disease phenotypes.10  
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Purpose  
 The purpose of this manuscript is to examine the concurrent validity of the 
PDMS-2 with the AIMS, the PEDI and the PPEDI in a sample of children with 
Pompe disease undergoing enzyme replacement therapy. The study involved 
secondary data from the Genzyme Corporation Pompe AGLUO 1602 and 1702 
enzyme replacement therapy (ERT) clinical trials.  
 Use of this data set provides an opportunity to evaluate concurrently 
validity of the PDMS-2 in children with a significant level of motor impairment and 
variable levels of functional mobility. These data analyses may help to inform 
clinical decision making for Pompe disease and future clinical trial outcome 
design. It may also identify strengths and limitations of the PDMS-2 that have 
application to a larger range of developmental disabilities. 
 Innovative therapies are continually being developed to extend survival for 
children with rare diseases. Intervention efficacy needs to include not only 
survival and motor capacity outcomes but also indicators to measure level of 
disability in activities of daily living. Evaluation of the concurrent validity of the 
PDMS-2 and PEDI and PPEDI allows measurement of the relationship between 
gross motor skill performance in the clinic and function in the home and 
community environment for children with Pompe disease. 
 A secondary purpose is to evaluate the concurrent validity between the 
PEDI and the PPEDI. Numerous changes were made to the PEDI to make it 
more appropriate for use in Pompe disease. It has become widely used in the 
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Pompe literature and is recommended for use in the Pompe Registry, but limited 
research is available to support validity for use. 
Research Questions: 
1. In the AGLUO 1602 subjects, what is the relationship between the 
PDMS-2 gross motor subtest percentile and age equivalent scores and 
the AIMS percentile and age equivalent scores? Are the relationships 
similar for the baseline assessment at ≤7.2months and the first 
assessment completed after 12 months of age? 
2. In the AGLUO 1602 subjects, what is the relationship between the 
PDMS-2 GMQ percentile scores and the AIMS percentile scores? 
3. In the AGLUO 1602 and 1702 subjects, what is the relationship 
between the PDMS-2 gross motor subtest percentage scores and the 
PPEDI Functional Skills Mobility scaled scores?  
4. In the AGLUO 1602 and 1702 subjects, what is the relationship 
between the PPEDI Functional Skills Mobility scaled scores and the 
PEDI Functional Skills Mobility scaled scores? 
5. In the AGLUO 1602 subjects, what is the relationship between the 
PPEDI Functional Skills Mobility scaled scores and the AIMS 
percentage scores? 
 Based on the review of literature, it was hypothesized that the strongest 
relationship involving the PDMS-2 would be present between the Locomotion 
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subtest and the AIMS, and that the strongest relationship would be present in the 
less than seven month age range.6,7,8  The PPEDI was hypothesized to have a 
stronger relationship with the PDMS-2 than the PEDI, due to the  inclusion of 
additional items on the PPEDI to reflect clinically relevant skills for children with 
Pompe disease. A strong relationship was hypothesized between the PPEDI and 
PEDI Functional Skills Mobility dimensions. A stronger relationship between the 
PPEDI and the AIMS was hypothesized in the assessments at one year and 
older than in those for infants less than 7.2 months old. 
Participants 
 The AGLUO 1602 clinical trial involved children from one month to 7.2 
months of age at baseline. The AGLUO 1702 clinical trial involved children from 
six months to 42 months of age at baseline. Ten children from the AGLUO 1602 
data had scores available to complete the AIMS analyses. The mean age for the 
first assessment period was 5.0 months (SD 2.2) and the mean age for the 
second assessment period was 16.0 months (SD 4.0). An additional seven 
children from AGLUO 1702 had data available to examine the relationship 
between the PDMS-2 and the PPEDI and PEDI.  The AGLUO 1702 children had 
a mean age for the first assessment period (baseline) of 22.7 months (SD11.5) 
and the second assessment period (week 52) of 34.8 months (SD13.1). The 
overall gender distribution was 6 females and 11 males. 
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Procedure 
 The AGLUO 1602 and 1702 data were collected by physical therapists in 
the USA, Taiwan, Europe and Israel. The primary author of this manuscript 
collected USA clinical data and assisted with international reliability training. 
Reliability training included a review of the theoretical basis for each assessment, 
instruction on administration guidelines and data reporting, and establishing inter-
rater reliability of 90% agreement for all of the tests.  To minimize investigator 
bias, the assessors did not review previous scores prior to administration of a 
repeat assessment. The same therapist at each site administered all repeat 
assessments. All concurrent assessments were completed on the same day at 
each interval.  Following administration of the assessment, score sheets were 
forwarded to central scoring and entered into a database.  
PDMS-2 
 The PDMS-2 was administered according to the guidelines in the manual. 
Four subtests make up the PDMS-2 gross motor composite: Reflexes, 
Stationary, Locomotion, and Object Manipulation.4 The Reflex subtest is 
completed only for subjects less than 12 months of age, and Object Manipulation 
is used after 12 months of age. All items are scored on a three point scale, with 0 
indicating that the criteria for successful performance were not met, 1 indicating 
the behavior is emerging, and 2 indicating successful performance of the item 
criteria.4 The PDMS-2 raw subtest scores were used to calculate standard 
percentile and age equivalent scores. PDMS-2 standard subtest scores and 
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motor quotients are calculated using normative age data.13 The gross motor 
subtest standard scores are used to calculate the overall Gross Motor Quotient 
(GMQ). Subtest raw scores were converted to percentage scores to complete the 
concurrent validity analysis with the PPEDI Functional Skills Mobility dimension 
scaled scores. The percentage score was calculated by dividing the obtained raw 
score by the maximum possible raw score and multiplying by 100.13   
AIMS  
 The AIMS was administered according to the guidelines provided in the 
manual. Administration involves observation of 58 items that measure weight 
bearing, posture and antigravity movement in supine, prone, sitting and standing 
positions.5  Typical play is observed with minimal handling. The items between 
the infant’s least and most mature item in each position create a “window” of 
current skills.5   Infants are given credit for all observed items in the “window” and 
for items that fall maturationally below the window.5 The total AIMS score is the 
sum of the four positional scores.  The total AIMS score and the age at the time 
of assessment are used to determine the percentile ranking compared with a 
normative age matched sample.  
 Liao and Campbell described the AIMS as a valid instrument to measure 
motor ability in infants and to evaluate different positions in space.14 They 
examined the item structure of the AIMS and confirmed that the items found in 
each testing position were presented in order of difficulty.14   Low precision for 
differentiating between levels of function was found with age equivalent items 
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greater than nine months of age.14 Authors stated that this was due to lack of 
items to measure change in performance after the child had achieved controlled 
lowering from standing to sitting.14 A systematic review of nine infant motor tests 
found that the AIMS demonstrated the strongest clinical utility and psychometric 
properties and was one of the best predictive measures for identification of 
atypical motor development.15 
PEDI and PPEDI 
 The PEDI is a standardized instrument for children aged 6 months to 7.5 
years that uses parent report to measure level of disability in self care, mobility 
and social function domains.10 The PPEDI is a Pompe disease specific version of 
the PEDI.  The PEDI and the PPEDI both measure Functional Skill and level of 
Caregiver Assistance in Self Care, Mobility and Social Function domains.  Each 
item is scored 0 if the child is unable to complete and 1 if the child can 
successfully complete the item. The total raw, standard, and scaled score with 
standard errors can be calculated for each domain. The Functional Skills-Mobility 
domain contains items that are relevant for daily independence in mobility 
function such as toilet, chair, wheelchair, bed, tub and car transfers; bed mobility; 
indoor and outdoor mobility; and stair ascent and descent.  The PEDI was 
administered following completion of the AIMS and the PDMS-2.  Credit was 
given for items observed in the outcome measures.  Parent report was used to 
complete the remaining items.  
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Data Analysis 
 The strength of the relationships between outcome measures was 
examined using correlation analysis with Pearson Product Moment correlation 
coefficients.  The correlations were examined at baseline and at the first 
assessment period after one year of age for AGLUO1602 and at baseline and 52 
weeks later for AGLUO1702. Each correlation analysis was interpreted using 
descriptive terms to define the strength of the relationship. Portney and Watkins 
criteria were used to judge the strength of the correlation coefficient, with 0.00-
0.25 indicating little or no relationship, .26 to 0.50 indicating a fair degree of 
relationship, 0.51 to 0.75 indicating a moderate to good relationship, and 0.76-
1.00 indicating a good to excellent relationship.16 The significance of the 
correlation coefficients was evaluated using p-values.  
 Research question #1, comparing PDMS-2 and AIMS scores, also 
included calculation of frequencies of agreements between the age equivalent 
scores on the AIMS and the PDMS-2 GMQ.  Frequency of agreement was 
measured within one, two, three and four months. 
Results 
PDMS-2 and AIMS 
 The Pearson product-moment correlations between the PDMS-2 gross 
motor subtests and the AIMS age equivalent and percentile ranking scores are 
presented in Table 1.  The age equivalent correlations indicate a good to 
excellent relationship (r =.75 -.95, significant p-values) in both age groups, for all 
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subtests except the Object Manipulation subtest (r=. 43, p-value non-significant). 
Only one of the percentile rank correlations was significant, the Locomotion 
subtest in the youngest age group (r= .67, p.033). A value of .67 indicates a 
moderate to good relationship between the Locomotion subtest and AIMS 
percentile rank scores. 
 Table 2.presents the mean AIMS and PDMS-2 gross motor subtest 
percentile ranks and age equivalent scores for each age group.  The mean 
percentile rank in the ≤7.2 month assessments was larger for the PDMS-2 gross 
motor composite (16.0) than the AIMS total score (11.6). The mean percentile 
rank in the ≥one year assessments was larger for the AIMS total score (34.8) 
than the PDMS-2 gross motor composite (28.4). Table 3 shows the percent 
agreement for the age equivalent scores for the combined age groups.  
PDMS-2 and PPEDI/PEDI 
 The Pearson Moment correlation coefficients between the PDMS-2 
subtest percentage scores and the PPEDI Functional Skills scaled scores are 
presented in Table 4. For the children in the AGLUO 1602 clinical trial, significant 
correlations in the youngest age group were present only for the Locomotion 
(r=.76, p.01) and Stationary (r=.83,p.003) subtests. Both correlations fell in the 
good to excellent range. For the children who were one year of age and older, 
the values for the Locomotion (r=.63, p .051) and the Stationary (r=.68,p .029) 
subtests fell in the moderate to good range.  Correlations for the Reflex subtest in 
the ≤ 7.2 months age group and the Object Manipulation subjects in the ≥one 
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year of age group were not significant.  In the AGLUO 1702 subjects at week 52, 
the correlation coefficients increased for both the Locomotion and Stationary 
subtests and remained non-significant for the Object Manipulation subtest. A 
moderate relationship was demonstrated between the PPEDI Functional Skills 
Social dimension and the Stationary subtest (r=.60, p.012). The PPEDI 
Functional Skills Self Care dimension demonstrated a moderate to good 
relationship with the Locomotion subtest (r=.64, p.0057) and a good to excellent 
relationship with the Stationary subtest (p=.79, p.0002).  
 The correlations for the relationship between the PEDI and the PDMS-2 
subtest percentage scores were Locomotion subtest (r=.90,.0001), Stationary 
subtest (r=.85,.0071),and Object Manipulation subtest (r=.21,.5794). The values 
were very similar to the correlations between the PPEDI and the PDMS-2, 
Locomotion subtest (r=.76.0004), Stationary subtest (r=.83,.0001), and Object 
Manipulation subtest (r=.33,.1869). 
PPEDI and AIMS 
 The Functional Skills Mobility dimension scaled scores and the AIMS had 
a moderate to good relationship (r=.70, p <. 0001) for children ≥one year of age, 
and a good to excellent relationship (r=.76, p <. 0001) for children ≤7.2 months of 
age.  
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PPEDI and PEDI 
 The PPEDI and PEDI Functional Skills Mobility dimension scaled scores 
had a moderate to good relationship (r=.69,<.0001) for children ≥ one year of 
age.  
Discussion 
PDMS-2 and AIMS 
 The hypothesis that the Locomotion subtest would have the strongest 
subtest relationship between the AIMS and the PDMS-2 was not supported by 
the age equivalent results. Although, similar to Synder et al( 2008) 6 the 
Locomotion values were slightly larger than the other subtests, all age equivalent 
values fell in the good to excellent range except  for Object Manipulation.6 It is 
reasonable to expect a lower correlation value for the Object Manipulation 
subtest due to differences in item content between the tests. The Object 
Manipulation subtest contains ball throwing, catching and kicking skills and the 
AIMS contains no items with ball skills. The Stationary results are in contrast to 
the Provost et al (2004) study that found non-significant age equivalent 
correlations between the BSID-II and the PDMS-2 for the Stationary and Object 
Manipulation subtests.7 Provost was able to evaluate the PDMS-2 and BSID-II in 
a large age range, from three to 41 months. The range may have been more 
suitable for capturing possible standing limitations on the Stationary subtest. 
 The PDMS 2 developers suggest that caution should be used when 
interpreting test results with age equivalent scores.4   They recommend use of 
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standard and percentile scores when interpreting test results.4 This study found 
that the age equivalent correlations were higher than the percentile rank 
correlations. The percentile rank Locomotion subtest values were in the good 
and good to excellent range but the Stationary subtest had only a fair relationship 
in the youngest group (≤7.2 months) and a non-significant p-value for the older 
group (≥one year of age). Non-significant p-values were also found for the Reflex 
subtest in the youngest group and the Object Manipulation subtest for the older 
group. The percentile values from this research may support utility of the 
Locomotion subtest as a discriminate measure in children diagnosed with Pompe 
disease. Additional research with a larger sample size would be beneficial to 
determine with more precision the strength of the relationships in all of the 
subtests.  
 The relationship between the percentile rank scores for the PDMS-2 and 
the AIMS was lower in the ≤7.2 month than the ≥one year age group for the 
Stationary and Locomotion subtests. The AIMS also had a lower mean percentile 
rank than the PDMS-2 GMQ in the younger group.  These findings might reflect 
differences in the item content of the AIMS and the PDMS-2 for the younger 
children. Infants with Pompe disease often have general hypotonia and proximal 
weakness. The AIMS contains items that qualitatively measure trunk strength in 
supine such as chin tuck with active abdominal muscles for hands to knees, and 
prone items that require not just a measurement of head elevation, but an active 
chin tuck with neck elongation and chest elevation.5 In contrast, the PDMS-2 
contains items that measure head alignment relative to the trunk with examiner 
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facilitated movements or sitting postures, and prone is measured through head 
and upper trunk elevation as a timed task. The AIMS may contain more items 
than the PDMS-2 Stationary and Locomotion subtests to capture the specific 
weakness deficits that are seen in infants who present with Pompe disease. 
 The non-significant correlation between the AIMS and Stationary subtest 
percentile rank scores in the older age group may also be explained by the 
typical motor presentation of children with Pompe disease. Infants with Pompe 
disease often have more lower than upper extremity impairment and 
demonstrate delayed independent standing and ambulation.17 The Stationary 
subtest has an item progression from tall kneeling to standing on one foot 
independently.  It lacks items to capture quality of movement in supported 
standing and emerging independent standing. The AIMS, in contrast, has 
numerous items to capture quality of standing such as rotating in supported 
standing, standing alone, and lowering from standing to the floor.  PDMS-2 
results for the Stationary subtest do not indicate whether the child’s skills are 
closer to the tall kneeling item or the standing on one foot item.  If a child was 
able to tall kneel, and stand at a support surface, but unable to achieve standing 
on one foot, the maximum item credit would be for tall kneeling. On the AIMS, the 
same child would receive credit for standing items, and the relationship between 
motor skill acquisition as measured by the two assessments would be reduced.   
 The correlation coefficient between the PDMS-2 GMQ and AIMS 
percentile rank for the combined age groups was statistically significant. In 
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previous investigations PDMS-2 individual subtest shortcomings may have been 
masked due to averaging of the three scores to obtain one test score.  
PPEDI 
 A comprehensive evaluation of function in children with Pompe disease 
should not be limited to assessments that evaluate capacity to perform motor 
skills in the clinic environment. Function should also be considered within the 
context of environment. Activity limitations and participation restrictions within the 
community, home, and school environments should be considered.  Correlation 
coefficients between the PPEDI Functional Skill Mobility dimension and the 
PDMS-2 Stationary and Locomotion subtests were in the good to excellent 
range.  This demonstrates that motor capacity on the PDMS-2 reflects actual 
performance on the PPEDI. The hypothesis that the Locomotion subtest would 
have a stronger relationship with the PPEDI than the other subtests was not 
supported. All Locomotion and Stationary values fell into the moderate to good or 
good to excellent range. The Reflex subtest had a non-significant, fair 
relationship with the PPEDI. This finding may reflect differences in item content, 
because the PPEDI measures function in children with developmental disability, 
and the PDMS-2 Reflex subtest measures reflexes and righting reactions seen in 
typical development.  
 Correlation coefficients between the PPEDI Functional Skill Mobility 
dimension and the AIMS were also in the good range.  This adds support for the 
capacity of the PPEDI to measure motor function in the home and community 
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environment. A systematic review of nine infant motor tests found that the AIMS 
demonstrated the strongest clinical utility and psychometric properties and was 
found to be one of the best predictive measures for identification of atypical 
motor development.15 
 The Object Manipulation subtest had a non-significant p-value at ≥ one 
year of age, but a good to excellent range value 52 weeks later. The PPEDI does 
contain ball skills similar to the Object Manipulation subtest, but the children at 
the younger ages may not have had the standing capacity to demonstrate the 
ball skills until they were older.  
 The PPEDI and PDMS-2 coefficient correlation values were much larger 
than those reported for the PEDI in children with language deficits and mild motor 
issues.9 One explanation for differing results is that children diagnosed with 
Pompe have much greater motor impairment than the mild motor issues present 
in the Mayrand et al population.9 Secondly, the inclusion of additional items on 
the PPEDI Functional Skills Mobility dimension, as compared to the original 
PEDI, may have increased the precision of the instrument for use in Pompe 
disease. 
Eligibility for Intervention Services. 
 Eligibility for early intervention services requires providers to demonstrate 
developmental delay relative to a normative peer sample. Standards for 
determination of eligibility for early intervention services are variable between 
counties and states.  Variability is also present in tool selection. The AIMS 
 78 
developers did not provide a recommendation for definitive percentile rank 
interpretation to justify therapy referral for intervention. They recommended 
pairing a low percentile ranking with “ongoing monitoring, referral for diagnostic 
workup or intervention for motor delay” (page 49).5 Van Haastert et al (2006) 
used pediatrician developmental assessments to establish AIMS percentile 
values of normal, suspect, and abnormal in premature infants.18 The 10th 
percentile rank at four months of age produced a sensitivity of 77% in predicting 
abnormal movement at 18 months of age. If a 10th percentile rank was chosen 
as the most accurate level for determination of “abnormal movement” and 
qualification for early intervention services, five children in the present study 
would qualify using the PDMS-2 scores and ten would qualify with use of the 
AIMS scores. The PDMS-2 manual recommends interpretation of standard 
scores of  < 79 on the GMQ as an indicator of “poor” gross motor movement.4 If 
PDMS-2 GMQ of 79 or less was used as the criterion for service eligibility in the 
present study, seven children would qualify for therapy services. If the AIMS and 
the PDMS-2 both used a percentile score cut off level < 25%, an equal number of   
twelve children would qualify for therapy services.  
 A lack of agreement between the AIMS and the PDMS-2 percentile scores 
and variable interpretive standards can create inequities in service eligibility 
between agencies and geographic regions. Therapists should be encouraged to 
concurrently administer more than one developmental motor outcome tests if 
possible.   Documentation of outcome scores should be paired with detailed 
narratives and use of clinical judgments for referral to agencies. Multidisciplinary 
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education that includes physicians and parents should be completed to provide 
clarity on test interpretation. 
Limitations 
 Direct application of these results is limited to a small population of 
children with Pompe disease. Concurrent validity was completed only on a small 
range of the PDMS-2, from 0 to 72 months administrative age. The sample size 
of this study was small, and non-significant p-values may have been due to 
inadequate statistical power. Additional research with a larger sample size is 
justified to determine the reproducibility of the results. 
Conclusion 
 The study results demonstrate that, in children with Pompe disease, a 
stronger relationship was present between the PDMS-2 and AIMS age equivalent 
scores than the percentile scores. The relationship between the PDMS-2 and 
AIMS was strongest in the Locomotion subtest percentile scores. 
 Motor capacity on the PDMS-2 and the AIMS reflects actual performance 
in the home, school, and community environment as measured on the PPEDI in 
this sample of children with Pompe disease. PPEDI Functional skill Mobility 
dimension correlation coefficients between the PDMS-2 Stationary and 
Locomotion subtests and between the AIMS were in the moderate to good or 
good to excellent range. Item content differences may be present between the 
PPEDI and the Reflex and Object Manipulation subtests with administration to 
infants. The correlation coefficient results between the PPEDI and the Reflex and 
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Object Manipulation subtests in the <=7.2 month group indicated a non-
significant, fair relationship.  
 A four-month range in age equivalent scores was necessary to achieve 
100% agreement between the AIMS and the PDMS-2 gross motor subtests. Use 
of more than one developmental motor outcome measurement to determine 
eligibility for services is recommended.  
 
 
 
Table 1. 
Pearson Product Moment Correlation Coefficients (r) a for the Age 
Equivalent and Percentile Scores of the PDMS-2 Subtests and GMC b, and 
the AIMS c 
Score 
Age 
Equivalent 
Age 
Equivalent 
Percentile 
Rank 
Percentile 
Rank 
Percentile 
Rank 
Evaluation Age 
≤7.2m 
 
≥1yr ≤7.2m 
 
≥1yr Both 
Groups 
Reflexes .75(.0117)*  .46(.1774)      
Locomotion .91(.0003)* .97(.0013)* .67(.0326)* .87(.1271)  
Stationary .86(.0015)* .96(.0028)* .36(.3114) .57(.4324)  
Object 
Manipulation   .43(.4713)   .92(.2531)  
Gross Motor 
Composite      .69(.0032)* 
a Pearson Product Moment Correlations  displayed as r ( p value) 
b PDMS-2: Peabody Developmental Motor Scales- 2nd edition- Gross Motor Composite 
c AIMS: Alberta Infant Motor Scale 
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Table 2. 
Mean Age Equivalent and Percentile Rank Scores for the PDMS-2 GMC a 
and the AIMS b  
Score 
Age 
Equivalent 
Age 
Equivalent 
Percentile 
Rank 
Percentile 
Rank 
Evaluation Age ≤7.2m ≥1yr ≤7.2m ≥1yr 
PDMS-2  
GMCa 2.1m 9.3m 16.0 28.4 
AIMSb 2.0m 10.4m 11.6 34.8 
a PDMS-2 GMC- Peabody Developmental Motor Scales Gross Motor Composite 
b AIMS Alberta Infant Motor Scale 
c m= Months 
 
 
Table 3. 
Percent Agreement in Age Equivalent Scores for the PDMS-2 GMC a and    
AIMS b 
 Time  % Agreement 
1 month 50.0  
2 months 68.8 
3 months 87.5 
4 months 100.0 
a PDMS-2 GMC-Peabody Developmental Motor Scales Gross Motor Composite 
b AIMS-Alberta Infant Motor Scale 
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Table 4. 
Pearson Product Moment Correlation Coefficients(r)a for the PDMS-2b 
Subtest Percentage Scores and the PPEDIc Functional Skills Dimension 
Scaled Scores 
PDMS-2 
PPEDI 
Functional 
Skills: 
Mobility  
PPEDI 
Functional 
Skills: 
Mobility 
PPEDI  
Functional 
Skills: 
Mobility 
PPEDI  
Functional 
Skills: 
Mobility 
PPEDI  
Functional 
Skills: 
Social 
PPEDI  
Functional  
Skills: Self 
Care 
 
AGLUO 
1602 
≤7.2m 
AGLUO  
1602 
≥1yr 
AGLUO 
1602 & 1702 
≥1yr 
AGLUO 
1702 
Week 52 
AGLUO 
1602 
 ≥ 1yr & 
 1702 
Baseline 
AGLUO 
1602 
 ≥ 1yr & 
1702 
Baseline 
Reflexes .49(.155)        
Locomotion .76(.010)* .63(.051) .76(.0004)* .85(.031)* .26(.318) .64(.0057)* 
Stationary   .83(.003)* .68(.029)* .83(<.0001)* .93(.023)* .60(.012)* .79(.0002)* 
OMd   .39(.268) .34(.1869) .81(.052) -.10(.710) .04(.8881)  
Sample 
Size 10 10 17 6 17 17 
Mean Age 
months 
(SD) 5m(2.23) 15.96m(3.96) 18.7m(8.6) 34.8m(13.1) 18.7m(8.6) 18.7m(8.6) 
a Pearson Product Moment Correlations  displayed as r ( p value) 
b PDMS-2- Peabody Developmental Motor Scales- 2nd edition 
c PPEDI -Pompe Pediatric  Evaluation of Disability Inventory 
d OM-Object Manipulation 
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Chapter IV. 
 Synthesis 
Summary of Results 
 The PDMS-2 is extensively used as an evaluative and discriminative 
measurement tool in clinical research, early intervention and rare disease clinics, 
and school systems. Golumb et al (2004) reviewed 517 articles on motor 
outcomes used in young children and found that the PDMS-2 was one of the four 
most commonly cited measurement tools.1 Yet there is a paucity of validity 
research to support use with children with chronic diseases and moderate 
developmental disability, and guidelines are absent on how to interpret standard 
scores as a measurement of change in motor function.  Secondary analyses of 
Genzyme Corporation Pompe disease AGLOU 1602 and 1702 data provided a 
unique opportunity to analyze responsiveness to change and concurrent validity 
of the PDMS-2 in children with a significant motor impairment. 
 Although the focus of this dissertation was to examine the PDMS-2 validity 
in children with Pompe disease, the identified limitations of use may be 
appropriate to consider with other diagnoses. The functional distribution of the 
sample was not dissimilar to what might typically be seen in pediatric clinic 
environments. Children with other diagnoses can present similar to functional 
group one with generalized weakness, delayed acquisition of independent 
ambulation and challenges with high-level balance and coordination skills, or 
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similar to functional group two with the ability to sit independently, required use of 
adaptive equipment to ambulate or stand, and primary community mobility with a 
wheelchair.  
 The results of this study support adequate responsiveness of the PDMS-2 
in a heterogeneous group of children who present with Pompe disease.  
However, “responsive measures discriminate between trivial and substantial 
change within groups and between those groups.” 2 (page 3) When 
responsiveness to change was evaluated in two different functional 
presentations, the Locomotion subtest was able to discriminate change within 
both groups from baseline to week 52 and between groups at both time frames. 
The Stationary subtest was unable to discriminate between or within groups. The 
Object Manipulation subtest was able to discriminate change only within group 
one from baseline to week 52 and between functional presentations of group one 
and group two at week 52. The validity of a tool depends on the number of 
values on the instrument and the standard error of measurement of the 
instrument.3 The more items on the instrument, and the smaller the standard 
error of measurement, the greater the opportunity to detect change.3   Content 
validity defines the extent to which the items reflect a content domain and it is 
clear that no items are missing. The Stationary subtest may lack content validity 
and adequate responsiveness when level of function is considered due to an 
inadequate number of test items to quantify quality of bipedal standing and 
transitions in and out standing. Thirteen out of fourteen children had a week 52 
raw score between 36 and 38.  This represents a ceiling effect at either item #19, 
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maintaining balance in tall kneeling, or item #20, standing on one foot for three 
seconds.  
 An Object Manipulation subtest ceiling effect was also present for children 
who did not have the ability to balance in standing independently and complete 
ball skills.  Children with a greater degree of developmental disability with an 
inability to maintain independent standing could not progress on the Object 
Manipulation items. 
 Acceptable responsiveness was present in the PDMS-2 percentage GMC 
scores when the functional groups were separated or combined. The GMC was 
calculated by summing the three gross motor subtests and then dividing by three 
to create an average score. A large change score in the Locomotion subtest 
could compensate for a small Stationary subtest change score and create an 
overall significant mean difference between the GMC at baseline and week 52. 
Although the testing time frame for this research was 52 weeks, clinical 
reevaluations for reauthorization of therapy services often need to be completed 
every three to six months. Over this shorter time frame, a smaller change in 
Locomotion subtest score may be present. A smaller Locomotion subtest change 
score, paired with the same lack of change on the other two subtests, may not 
produce a significantly different mean GMC change score. Wang et al (2006) did 
find acceptable GMC responsiveness with a three-month testing interval in 
children with cerebral palsy, but the research combined subjects with mild and 
severe cerebral palsy into one group and did not evaluate individual subtests.4 
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 Response indices values indicate that the Locomotion subtest and the 
GMC were more responsive to change in functional group one than two. The ES 
is calculated by dividing the mean change score by the pooled standard deviation 
of the baseline and week 52 scores. Functional group one had a larger mean 
change score and less variance in scores than functional group two, thus 
creating larger response indices. The Stationary subtest response indices were 
large in both functional groups and did not support lack of responsiveness to 
change. Effect size is affected by group variance, and the Stationary subtest had 
a very small score variance, thus creating large effect sizes. Therefore the ES 
and SRM should be interpreted with caution because the lack of items to capture 
standing function actually created a large ES. 
 Examination of concurrent validity of the AIMS and the PDMS-2, yielded 
results that demonstrate a stronger relationship between age equivalent scores 
than the percentile scores. Although the Locomotion values were slightly higher 
than the other subtests, all age equivalent values except Object Manipulation fell 
in the good to excellent range.  The PDMS-2 developers suggest that caution 
should be used when interpreting age equivalence scores and recommend use 
of percentile rank scores. The percentile rank Locomotion subtest values were in 
the good, to good to excellent range but the Stationary subtest had only a fair 
relationship in the youngest group and a non-significant correlation coefficient for 
the older group. This lends some support to research that has been completed in 
children with mild developmental delay that suggests that the Locomotion subtest 
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may have the best subtest discriminative utility.5 Additional research with a larger 
sample size is necessary to determine the reproducibility of the results.  
 Eligibility for early intervention services requires providers to demonstrate 
developmental delay relative to a normative peer sample. Variability in tool 
selection and standards for determination of eligibility for therapy services are 
present between evaluation centers. The AIMS developers do not provide a 
recommendation for definitive percentile rank interpretation for referral to therapy. 
Van Haastart et al (2006) used pediatrician developmental assessments to 
establish AIMS percentile values of normal, suspect and abnormal in premature 
infants.  The 10th percentile rank at four months of age produced a sensitivity of 
77% in predicting abnormal movement at eighteen months of age.6   If a 10th 
percentile rank was chosen as the most accurate level for determination of 
“abnormal movement”, and qualification for early intervention services, five 
children would qualify using the PDMS-2 scores and ten would qualify with use of 
the AIMS scores. A four-month range in age equivalent scores was necessary to 
achieve 100% agreement between the AIMS and the PDMS-2 in this research. A 
lack of agreement between the AIMS and the PDMS-2 percentile and age 
equivalent scores and variable interpretive standards can create inequities in 
service eligibility between agencies and geographic regions. Therapists should 
be encouraged to concurrently administer more than one developmental motor 
outcome test when possible.  Documentation of outcome scores should be 
paired with detailed narratives and use of clinical judgment.  
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 Inclusion of the PPEDI data in this dissertation provided an opportunity to 
examine a tool that is very commonly used in the Pompe literature and is 
recommended for use in the Pompe Registry.7 A comprehensive evaluation 
should include not just capacity to perform motor tasks in the clinic environment. 
It also should identify activity limitations and participation restrictions in the home, 
school, and community environments. The only validation research available for 
the PPEDI was completed in the initial test development. Given the PDMS-2 
shortcomings that have been identified in this research, it was beneficial to also 
compare the PPEDI to the AIMS. A systematic review of nine infant motor tests 
found that the AIMS demonstrated the strongest clinical utility and psychometric 
properties and was found to be one of the most predictive measures for 
identification of atypical motor development 8 The PPEDI Functional Skill Mobility 
dimension was significantly correlated with the PDMS-2 Stationary and 
Locomotion subtests and with the AIMS, with correlation coefficients in the good 
to excellent range.  This demonstrates that motor capacity on the PDMS-2 and 
the AIMS reflects actual performance on the PPEDI.  
Application to Clinical Practice and Research 
 The results from this research will inform future Pompe disease protocol 
development.  The clinical development team at Genzyme could not use the 
PDMS-2 data for FDA drug approval because they had no idea how to interpret 
the standard scores in efficacy research. They used raw AIMS scores beyond the 
age of recommended use to demonstrate motor skill acquisition in response to 
ERT. The published manuscripts from the clinical trials documented motor skill 
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acquisition without inclusion of any specific motor data. In view of the results from 
the present study, raw scores could be converted to percentage scores to 
demonstrate efficacy on the basis of changes in the GMC score and the 
Locomotion subtest score over the 52-week period. 
 Conversion of the PDMS-2 subtest raw scores into percentage scores 
may be beneficial for interpretation as an evaluative measure in other 
populations. Norm referenced standard scores are appropriate for use as a 
discriminative tool, but very challenging to use in evaluating change.   Accurate 
standard score interpretation by health care and school professionals, insurance 
agencies, and parents is essential to guide decision making and plan of care 
development. Normative mean standard scores are variable on pediatric motor 
tests, and interpretation of change is confusing. Professionals and parents may 
be unaware that the same standard score on two consecutive testing periods 
actually represents motor skill acquisition. The raw scores in this research were 
easily converted into percentage scores.  PDMS-2 percentage score use as a 
measurement of change in performance would be very similar to the percentage 
scores on the GMFM or the Scaled scores on the PEDI. 9, 10  
 This research highlighted the importance of functional classification of 
subjects in Pompe disease efficacy research.  Ongoing development of more 
detailed functional classification system for use in Pompe disease is 
recommended. The PDMS-2 may be most appropriately used in children with 
mild developmental delay, who have the capacity or potential to; balance in 
standing to complete ball skills and acquire higher standing skills like standing on 
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one foot. Use of the Locomotion subtest as a discriminative measure to define 
function relative to a normative sample may also be appropriate.  A wide 
heterogeneity is present in the functional presentation of children with Pompe 
disease, and functional course is not always predictable. If a study sample 
primarily involved children with significant motor impairment, adequate subtest 
responsiveness to change many not be present in the Stationary and Object 
Manipulation subtests.  
 Multidisciplinary education that includes physicians, parents, and 
insurance providers should be completed to provide clarity on test interpretation. 
Therapists must be educated in tool limitations in order to explain why a clinically 
significant change was observed but not represented on the standardized test 
scores or why variability exists between interagency evaluations.  
Limitations and Future Research 
 The primary limitation is that the results from both manuscripts are directly 
applicable only to the small population of children with Pompe disease. The 
concurrent validity examination is also applicable only to a partial range 
(0=18months) of the age span in which the PDMS-2 use is recommended for use 
(0-72months). The AIMS is appropriate for use only until 18 months of age. 
Additional studies on concurrent validity would be beneficial for the age group 
beyond 18 months of age. The BSID-III contains a gross motor subtest and is 
normed for use from birth to 64 months of age. It contains standard scores and 
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percentile scores that could be concurrently examined with the PDMS-2 in future 
research. 
 An additional limitation is that the 52-week interval between testing 
periods is longer than what is typically required for insurance authorization. It is, 
however, typical of the efficacy clinical trials for ERT. 
 It would be very interesting to look at a Rasch analysis of item fit in the 
Stationary and Locomotion subtests independently and then combined to create 
one motor subtest. Fluid administration in the clinic environment requires 
therapists to combine the subtests.  The Object Manipulation subtest is distinct 
from the other two subtests because it just evaluates ball skills. 
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Appendix One: Literature Review  
PDMS- 2  
 The PDMS-2 is a standardized, norm-referenced test that contains four 
subtests that make up the gross motor composite: reflexes, stationary, 
locomotion and object manipulation; and two subtests that make up the fine 
motor composite: grasping and visual- motor integration.1 The total motor 
composite includes items from all of the subtests.  All items are scored on a 3 
point scale, with 0 indicating that the criteria for successful performance were not 
met, 1 indicating the behavior is emerging and a 2 indicating successful 
performance of the item criteria.  The subtest raw scores can be used to 
calculate standard, percentile, z, and age equivalent scores. The subtest 
standard scores can be used to calculate gross, fine, and total motor composite 
quotient, percentile, and age equivalent scores.  Gross, fine, and total motor 
quotient scores have a mean of 100 with a standard deviation of 15.  The test 
developers recommend use of the motor quotient and percentile scores for 
interpretation of test results. 
 Inter-rater reliability of the PDMS-2 has been documented in the research 
for typically developing children (ICC of r=. 96-.99),1 children with cerebral palsy 
(ICC of r= .88-1.0),2 and children with Hurler’s Syndrome (ICC of r= .74-.98)3 for 
the GMQ, raw scores and age equivalent scores. Reliability defines the accuracy 
or repeatability of the test when administered on different occasions or by 
different test administrators.  Reliability is often misinterpreted by physical 
therapists as the only key component in choosing a test. Increased reliability 
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does increase the probability of detecting a difference between two groups, but it 
will not tell us if the variable is measuring what we want it to. A test also can be 
reliable but lack validity in terms of measuring important key constructs.  
 The Taxonomy of the Psychomotor Domain by Harrow (1972) was the 
foundational construct for the PDMS-2.1 The taxonomy assumes that 
development follows a hierarchical sequence of skill acquisition that begins with 
reflexive behavior and progresses through basic fundamental movements.1 The 
PDMS-2 test administration requires basal level item entry, with successful credit 
for three consecutive 2’s, and ceiling level discontinuation, with three consecutive 
0’s.  Children are credited for all items below the basal level, but not items above 
the ceiling level.  This is in contrast to the Alberta Infant Motor Scale (AIMS), 
another commonly used norm-referenced tool. The AIMS  is based on the 
dynamic systems model, and children are given credit for all items observed on 
the measurement tool.4 The hierarchical design of the PDMS-2, with lack of credit 
for skills above the ceiling level, may limit validity due to an inability to capture 
motor functional ability in children who do not demonstrate a predictable rate or 
sequence of skill acquisition.  
 An outcome measure is valid if it measures what it is designed to measure 
and accurately reflects the clinical findings.  Validity has also been defined as the 
evaluative summary of the evidence for use and the potential consequences of 
score interpretation.5 The validity of a tool is not an absolute value, because it 
varies according to the purpose of use and the population of subjects tested.6 
 The PDMS-2 continues to expand in its clinical and research application.   
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Measurement of the PDMS-2 test validity should be an ongoing process to define 
appropriate use with a conclusive body of research.  Construct, content, and 
criterion validity, as well as responsiveness, are key components that will be 
reviewed in the PDMS-2 manual and literature.  
 Construct validity indicates the degree to which a measurement reflects an 
operational definition.7  The construct validity of an instrument may evolve over 
time with changes in the understanding of the construct of interest. Based on the 
Taxonomy of the Psychomotor Domain the PDMS-2 developers defined 
nonlocomotor movements (stationary subtest) as “movements of the limbs and 
trunk, bending, extending stooping and twisting.”1 Conceptually for physical 
therapists, “nonlocomotor” or stationary skills may be considered as static 
balance or the ability to maintain center of mass within limits of stability without 
having to use a protective or equilibrium strategy.   Test administrators may 
equate the term stationary more with the ability to maintain balance in sitting and 
standing than “movements of the limbs and trunk, bending, extending stooping 
and twisting”. There are items on the Stationary subtest that measure sitting and 
kneeling balance, but there are no items on the subtest that capture standing 
balance abilities.  Construct validity for the PDMS-2 was reported in the test 
manual through a confirmatory factor analysis of the subtests and motor 
composites.  Confirmatory factor loading for the 12-72 month gross motor 
composite was .79 for the Locomotion subtest and only .52 for Stationary and .40 
for Object Manipulation subtests. 1 Confirmatory factor analysis implies that 
researchers have specified which items are related to each subtest, and then 
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factor loading confirms or refutes representation of that factor (subtest) by the 
variable (items).  Garson (2010) recommended loading of .70 or higher in 
confirmatory factor analysis to confirm that variables are reflected by the factor.8   
This brings into question whether the stationary subtest captures the theoretical 
construct of its’ current use and interpretation in the clinic setting.  Additional 
research with exploratory factor analysis would be necessary to evaluate whether 
several standing items currently included in the Locomotion subtest might factor 
favorably on the stationary subtest.  
 Content validity defines the extent to which the items reflect a content 
domain and it is clear that no items are missing.9 A measure has content validity 
when the items are randomly chosen from a list of items that could represent the 
variable. The PDMS-2 test developers report content validity with mean item 
discrimination coefficients in each subscale. In the Stationary subtest, the lowest 
discrimination coefficient, r=. 41, was found in the 36-47 months age group.1 In 
the Object Manipulation subtest, the lowest correlation coefficient of r=. 36 was 
reported in the 12-23 month range.1 In the Stationary subtest, an item 
progression is present from item #19 maintaining balance in kneeling for 5 
seconds to item # 20 standing on one foot for 3 seconds, with no items in static 
standing. Only one item is included with an age representation between 14 and 
42 months.  In contrast, the AIMS provides five items that qualitatively analyze 
stationary standing.4 In the Object Manipulation subtest, item administration 
progresses from item #3 rolling a ball in sitting to item #4 independently 
maintaining standing and flinging a ball 5 feet. On the Stationary and Object 
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Manipulation subscale, item gaps may decrease the instrument’s ability to 
measure the construct of interest and the tool’s responsiveness to change.  
 Responsiveness of a tool can be defined as the ability to measure 
clinically important change over time.2 It depends on the number of items and the 
standard error of measurement of the instrument. 7 The more items included on 
the instrument, and the smaller the standard error of measurement, the greater 
the opportunity to detect change. Wang et al (2006) evaluated the 
responsiveness to change of the PDMS 2 in children with cerebral palsy over a 
three-month period using paired t-tests, effect size, standardized response mean 
and the Guyatt Responsiveness Index. 2 Subtest raw scores were used to 
calculate percentage scores for the subtests. Subtest percentage scores were 
then used to calculate gross, fine and total motor composite percentage scores.  
Paired t-tests demonstrated that a statistically significant change (p<. 001) was 
present between the gross, fine and total motor percentage scores over 3 
months.  The effect size for the gross motor subtest percentage score was 
labeled as small at 0.2 according to Cohen standards.2 The standardized 
response mean for the gross motor composite was labeled as trivial at 0.9.  
Information was not included on individual subtests within the fine or gross motor 
composites.   A PDMS-2 review of the literature did not provide any additional 
research on the responsiveness of the PDMS-2 gross motor subtests or 
composite. Responsiveness research is applicable only to the sample population 
tested.  
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 Criterion validity is the degree to which the instrument reflects or is related 
to scores obtained on a well-established instrument or “gold standard”.7 
Concurrent validity is a method of criterion validity that evaluates the agreement 
between the results of two instruments administered within the same time 
period.7 Correlation coefficients from r=. 80-.91 were found between PDMS-2 
standard subtest scores and the Mullen Scales of Early Learning (MSEL) 
standard gross and fine motor scale in the normative sample.  The authors stated 
that the coefficients support equivalency between the tests, but no coefficient 
was provided between the MSEL gross motor value and the PDMS-2 Stationary 
subtest value, and the manual labeled the coefficient between the MSEL and the 
Stationary subtest as non-significant.   
 The PDMS-2 correlated well (r=0.76) with the Movement Assessment 
Battery for Children (MABC) in a sample of children with developmental 
coordination disorder between 4 and 6 years of age. 5 The MABC contains 8 
items divided into manipulative skills, ball skills and balance skills. The MABC 
was designed to evaluate children with mild to moderate motor impairment, and 
incorporates a standardized performance test and a criterion referenced 
observational checklist. The study excluded all subjects with a severe motor 
impairment such as cerebral palsy.  
 Synder et al (2008) examined the concurrent validity of the AIMS and the 
PDMS-2 gross motor subtests in infants who were at risk for motor delay, from 
birth to eighteen months of age. 10 The Pearson product moment correlations 
varied from r= .78 to 97. The largest most significant correlation coefficient of r=. 
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97 was found for the locomotion subtest in infants less than nine months of age. 
The emphasis in the AIMS is on qualitative evaluation of movement in supine, 
prone, sitting and standing, and includes transitional movements in each of the 
positions.  The locomotion subtest of the PDMS-2 includes transitional movement 
items. Inclusion of transitional items may provide an explanation for the higher 
correlation of the AIMS with the Locomotion subtest than with the Stationary 
subtest of the PDMS 2. 
 Provost et al evaluated the concurrent validity between the Bayley Scales 
of Motor Development- second edition (BSID-II) motor scale and the PDMS -2 in 
children who were referred for developmental evaluations.11 The BSID-II is a 
widely used discriminative and evaluative tool for children between 0 and 42 
months of age. The BSID-II and the PDMS-2 are often used to qualify children for 
eligibility for physical therapy services in early intervention. A correlation of 
r=0.75 between the BSID-II Psychomotor Index (PDI) and the PDMS-2 Gross 
Motor Index was demonstrated.  However, the tests were inconsistent in their 
ability to determine significant delay with standard scores.  More than 75% of the 
children who were classified as significantly delayed on the BSID-II (PDI <=69) 
did not score in the classification of “very poor” (TMQ =69) on the PDMS-2.11 The 
PDMS-2 Locomotion subtest showed a high age equivalent correlation of   r=. 97 
with the BSID-II PDI.  The Locomotion subtest also showed the highest age 
equivalent agreement with the BSID PDI at 96% within three months.  The 
Stationary and Object manipulation subtests had only a 90-95% agreement 
within five months.  A 5-month delay in a 20-month-old child equates to a 25% 
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delay in gross motor skills and supports eligibility for intervention services.  Lack 
of agreement between the two tests could represent variability in service 
eligibility. When tests are important for clinical decision making and service 
eligibility, Provost recommends a very high level of correlation (r=. 95).11 
 Concurrent validity between the PDMS-2 and the Bayley Scales of Infant 
Development-2 (BSID-II) also has been evaluated in typically developing, 12 
month old infants.12 The standard scores on the PDMS-2 GMQ and the BSID-II 
Motor Scale were not significantly correlated (r=. 30). No correlation was found 
between the age equivalent scores for the Stationary and Object Manipulation  
subtests, but a high and significant correlation (r=. 71 p<. 05) between the age 
equivalent PDMS-2 Locomotion and the BSID-II motor scale was found.  
 Literature is available to support concurrent validity of the PDMS-2 in 
typically developing children or children with mild developmental delay, but no 
research is available that supports concurrent validity in children with a chronic 
disease or moderate motor impairment. 1, 5 
PDMS-2 Summary 
 The PDMS-2 is a widely used discriminative and evaluative measurement 
tool that covers the age range from birth to 72 months. Evidence is lacking to 
support the validity of using the PDMS-2 as an evaluative measure for infants 
and children with a moderate or severe motor impairment. Construct, content, 
and concurrent validity studies document poorer psychometric properties for the 
stationary than the locomotion subtest.  The Stationary subtest age equivalence 
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item presentation gap from 13 months to 31-32 months, with lack of items to 
measure standing balance, may impact responsiveness to change. Large jumps 
in activity level required to pass items can decrease instrument precision. 13  True 
functional level cannot be determined because it is unclear if ability is close to the 
passed item or close to the failed item. Lack of responsiveness to change may 
be the most apparent for the child who has activity limitations in independent 
standing balance. 
Pompe Disease and the AGLU0 1602 and 1702 Clinical Trials 
 Pompe disease is a rare lysosomal storage disease characterized by a 
deficiency of the enzyme acid alpha glucosidase. (GAA) 14  Lack of GAA causes 
accumulation of glycogen in cardiac, skeletal, and smooth muscle and central 
nervous system tissue, leading to progressive cardiomyopathy, respiratory 
compromise, generalized weakness and hypotonia. 14 The natural history of 
infantile onset Pompe disease typically leads to death by 1 year of age.15  
 Muscle function in Pompe disease may be reduced by a combination of 
muscular and neurological impairments.  Glycogen accumulation has been found 
not only in the lysosomes, but also in the anterior horn cells, motor nuclei of the 
brain stem, and spinal ganglia. De Ruisseau et al16 found greater glycogen 
accumulation in the spinal cord than the brain, and noted absent or decreased 
deep tendon reflexes in individuals with the disease. Electromyography and 
nerve conduction studies have confirmed the presence of peripheral 
polyneuropathy in a two-year-old child with infantile Pompe disease. 17 
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 Numerous articles document greater lower extremity than upper extremity 
motor impairment in Pompe disease 14, 18 The studies are generally based on 
observation of decreased or absent ambulatory skills with preservation of upper 
extremity functional skills. No literature has used a standardized pediatric 
assessment to compare gross motor versus fine motor skill acquisition.  
 
 The Genzyme Corporation Pompe disease ERT clinical trials, AGLUO-1602 
and AGLUO-1702, involved administration of ERT with recumbinant human 
alpha glucosidase (rhGAA- Myozyme) to infants and children from birth to 36 
months of age at baseline. The study’s primary objective was to evaluate the 
safety profile of rhGAA as determined by the proportion of patients alive and 
ventilator free over the course of the treatment.15 A secondary efficacy endpoint 
was the effect of treatment on motor development from baseline, as measured by 
the AIMS and/ or the PDMS-2.15   The Pediatric Evaluation of Disability Inventory 
(PEDI) and the Pompe Pediatric Disability Inventory (PPEDI) measured change 
in disability index from baseline. A control group was not used. Previously, an 
epidemiologic study of the natural history of Pompe disease was completed to 
provide a historical control for the AGLUO-1602 and AGLO-1702 clinical trials.19 
 Many factors contribute to ERT response in infants and children with 
Pompe disease, including age, disease severity, age of initiation of ERT, GAA 
activity as measured by cross- reactive immunologic material (CRIM) and anti- 
rhGAA antibody titer levels. 20 The infants who began receiving ERT before 6 
months of age, but were unable to form a native enzyme GAA, responded poorly 
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to treatment in the trials, with no significant motor changes on the AIMS or 
PPEDI. Patients with a higher baseline median muscle GAA at baseline, an age 
of less than 12 months, and better baseline motor scores had the best response 
to ERT.  
 The AGLUO-1602 summary manuscript by Kishnani et al (2007)15 
reported that 100% of the infants survived to 18 months of age. Compared to the 
untreated historical control group, the risk of death was reduced by 99%, and use 
of ventilatory assistance was reduced by 88%.  Thirteen of 18 children from 
AGLUO-1602 demonstrated motor and functional changes on the AIMS and 
PPEDI.  At week 52, 7 children demonstrated the ability to walk independently, 3 
children could pull to stand independently and walk with one hand held, and 3 
children could sit and roll independently but were not able to demonstrate weight 
bearing in standing.15 The remaining five subjects did not demonstrate clinically 
meaningful change on the AIMS or PPEDI. The children with the largest change 
scores on the AIMS also demonstrated the most substantial functional gains on 
all three PPEDI domains (self-care, mobility and socialization).15 
 In the AGLUO-1702 clinical trial 16 of 21 children were alive at the end of 
52 weeks.21 Five patients died before week 28 due to cardiac or respiratory 
failure. At baseline, 5 children were invasively ventilated and 2 were 
noninvasively ventilated (via mask).  Of the 5 children who were invasively 
ventilated, 3 remained ventilated 24 hours a day, 1 reduced ventilation to 12 
hours a day and 1 child died.  Nicolino et al (2009) 21 documented an age 
equivalent motor change score in 13 of 21 children on the AIMS or PDMS-2 but 
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no scores or data analyses were included in the manuscript. The researchers 
reported that five children were able to walk independently and eight patients 
could sit independently. 21 The remaining eight patients made no significant 
motor development gains from baseline. 21 
 There is not an established level of clinically meaningful change for the 
AIMS, the PEDI or the PPEDI. The test developers for the PEDI recommend use 
of the standard error in interpretation. Greater certainly is present in equating a 
change score to improved functional performance if it exceeds 2x the standard 
error.22 Fourteen of 18 children in the AGLUO1602 trial had PPEDI scaled 
change scores that exceeded 2x the standard error.  Only one child out of 18 had 
a decline in skill on the AIMS but an improvement on the PPEDI.  
 Ten of 16 children in the AGLUO 1702 trial had a PPEDI scaled score 
change that exceeded 2x the standard error. Eight of the 10 children also 
demonstrated new item acquisition on the AIMS. The AIMS may not be as useful 
in clinical trials for Pompe disease with the child who is lower functioning 
because it measures quality of movement along a typical development 
continuum.  The requirements for antigravity movement limit item credit for many 
of the children who are more severely impaired with Pompe disease. Limited item 
credit may also be present for the child with non-classical presentation and 
compensatory movement patterns who does not follow a typical developmental 
pattern. AIMS responsiveness could also have been limited for children who 
were ventilator- dependent at baseline and have no tolerance for prone 
positioning. The AIMS requires observation of gross motor skills in supine prone, 
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sitting and standing. Elimination of ¼ of positional items could limit tool 
responsiveness. 
Administration Procedure for the AIMS, PEDI, PPEDI and PDMS-2  
 The PDMS-2 was concurrently administered with the AIMS, PEDI and 
PPEDI to 18 subjects under the age of 6 months of age (AGLUO -1602) and 21 
children between 6 months and 36 months of age (AGLUO -1702). Outcome 
measurement testing was completed at baseline, week 12, 26, 38, and 52. The 
PDMS -2 was administered and recorded, but never analyzed as a primary 
outcome measure in the literature. 
 The primary author of this proposal collected the USA clinical data and 
participated in international reliability training that included physical therapists 
from Taiwan, Europe and Israel.  Each physical therapist or physiotherapist who 
participated in the clinical trial received training regarding the specific outcome 
measurement tools being utilized and established inter-rater reliability. Training 
included a review of the theoretical basis for each assessment, preparation for 
and administration of each assessment, and logistics for reporting results. To 
minimize inter-rater variability in the current study, the same therapist 
administered the assessments to the same subjects. The AIMS and the PDMS-2 
employ objective definitions for item credit and a standardized scoring system. 
The PEDI and PPEDI manuals also contain standard scoring guidelines for item 
credit. The parent or primary caregiver was interviewed for the PEDI and PPEDI. 
 In addition, professional observation of each child’s functional behavior 
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was used. The same parent/ caregiver was interviewed on subsequent 
assessments. Video assessments of a child with Pompe disease and a typically 
developing child were used to establish inter-rater reliability of 90% agreement 
for all of the tests.  To minimize investigator bias, the assessors did not review 
previous scores prior to administration of a repeat assessment. Following 
administration of the assessment the score sheet was forwarded to central 
scoring for tabulation of total raw, standard, scaled, age equivalent and percentile 
scores for the individual tests.  
Additional Instruments 
AIMS  
 The AIMS is an observation tool for examination of postural control in 
infants. The intended purposes are to identify infants with developmental delay, 
to address the rate of motor development with repeated testing, and to identify 
infants with abnormal patterns of movement.4 Use is recommended for infants 
from birth through acquisition of independent walking. Administration involves 
observation of 58 items that measure weight bearing, posture and antigravity 
movement in supine, prone, sitting and standing. The examiner observes typical 
play with minimal handling for the “window of function,” and then infants are 
given credit for the items in the window and those that fall maturationally below 
the window. To determine the total AIMS score the sum of the four positional 
scores is calculated.  The total AIMS score and the age at the time of 
assessment are used to determine the percentile ranking compared with a 
normative age matched sample. Numerous articles look at the reliability and 
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validity of the AIMS, but recommendations have not been made for the 
determination of clinically important change.13  
 Liao and Campbell examined the item structure of the AIMS and 
confirmed that the items found in each testing position were presented in order of 
level of difficulty. 13 Low precision for differentiating between levels of function 
was found for age equivalent items greater than 9 months of age. This was 
primarily due to lack of items to measure change in performance after the child 
had achieved controlled lowering from standing to sitting.  Overall, the 
researchers characterized the AIMS as a valid instrument to measure motor 
ability in infants and to evaluate different positions in space. They recommended 
use of an additional tool like the PDMS-2 to measure motor development once a 
child has demonstrated the ability to transition in and out of standing 
independently. 
PEDI 
 The PEDI is a standardized instrument for children aged 6 months to 7.5 
years that uses parent report to measure level of disability in self care, mobility 
and social function domains. 23 Each of the three domains is measured as a 
Functional Skill with respect to the level of Caregiver Assistance required.  Each 
item is scored 0 if the child is unable to complete and 1 if the child can 
successfully compete the item. The total raw, standard, and scaled score with 
standard errors can be calculated for each domain.  
 110 
 The functional skills-mobility domain contains 59 items that are relevant 
for daily independence in mobility function such as toilet, chair, wheelchair, bed, 
tub, and car transfers; bed mobility; indoor and outdoor mobility; and stair ascent 
and descent. 23 Although the PEDI focuses on level of independence in mobility 
and ADL, research supports a high intra-class correlation coefficient for 
concurrent validity with the GMFM, an evaluative tool designed to measure gross 
motor function.24 
 Mayrand et al evaluated the association between the PDMS-2 gross motor 
scale and the Pediatric Evaluation of Disability Inventory (PEDI) functional skills 
mobility domain in children with language impairment.25 The study found a low, 
non-significant correlation (r=. 23), between the PEDI functional skills mobility 
domain and PDMS-2 gross motor scale in children with language impairment. 
The PEDI was designed for use with children with physical disabilities or 
combined physical and cognitive disability.26 Use may not be as appropriate for 
children with a primary language impairment and mild motor impairment. 
 PPEDI 
 The Pompe PEDI is a disease specific version of the PEDI that was 
developed to assess functional capabilities and performance in children with 
Pompe disease from 2 months of age through adolescence.23 Haley et al (2003) 
23 modified the original PEDI in order to more accurately define the level of 
physical functioning and disability that was present in children with Pompe 
disease.  
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 The PPEDI includes all of the items listed in the PEDI as well as additional 
items that are designed to reflect clinically relevant skills for children with Pompe 
disease.23 Items were added to the Functional Skills and Caregiver mobility and 
self-care scales to reflect the functional skills and deficits seen clinically in 
Pompe disease.   Fifty-nine items were added to the mobility domain and 17 new 
items were added to the self-care domains. The items were added to raise the 
ceiling, lower the floor, and increase evaluation of assistive technology and 
adaptive equipment and to improve precision of scoring and potential sensitivity 
to change. Norm based scoring was developed for these new items. Scoring 
algorithms for the PEDI were adjusted to reflect the new normative data for the 
Pompe PEDI. 
 The PPEDI was administered by telephone interview to 30 parents of 
children with Pompe disease.  Subjects were identified on the Glycogen Storage 
Disease Network (GSD) list serve.23 Study participants were between 6 months 
and 22 years of age, primarily male (76%) and Caucasian (86%) and lived in the 
USA, Canada, Germany, Spain, and England, with the majority from the USA. In 
the sample, only 10 of 30 children had some ability to ambulate, and all children 
presented with functional skills below age expected normative values. Test re-
test was done in a two week interval with a mobility domain intra class correlation 
coefficient of r= .98. Authors justified use of a separate assessment for mobility 
and self-care in Pompe disease due to the heterogeneous clinical functional 
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presentation found in Pompe disease and the challenges of classifying the 
disease phenotypes.23 
Summary 
 The AGLUO 1602 and 1702 data provide a unique opportunity to use the 
PDMS-2 to evaluate, in greater detail, the functional presentation of infants and 
children with Pompe disease. Motor gains in response to ERT have been 
documented in the literature without inclusion of a defined level of meaningful 
change or outcome measurements comparing upper extremity and lower 
extremity function.  Additional functional outcome data may help to define the 
impairment distribution between upper and lower extremity.  
 The validity of a tool is not an absolute value because it varies according 
to the purpose of use, and the population of subjects tested.5   Validity of use in 
children with Pompe disease has not been established with the PDMS-2. These 
data provide an opportunity to evaluate two key components of validity, 
responsiveness and concurrent validity.  
 The responsiveness of the PDMS-2 may be variable according to level of 
functional mobility. The stationary subtest item presentation gap may impact 
responsiveness to change as an evaluative measure. Large jumps in activity 
level required to pass items decreases the precision of the instrument. 13 Lack of 
responsiveness to change may be most apparent for children who present with 
activity limitations in independent standing balance. The large age range of the 
children and a heterogeneous level of functional mobility in the sample provide 
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an opportunity to measure responsiveness of the PDMS-2 in children with 
Pompe divided by level of functional mobility.  
 Concurrent validity can be evaluated between the PDMS-2, AIMS, PEDI 
and PPEDI with these data.  The AIMS is a qualitative evaluative instrument 
designed for use in infants between birth and 18 months of age. The relationship 
between PDMS-2 subtests and the AIMS can be examined in infants less than 
18 months of age at consecutive time points. Level of agreement on age 
equivalent scores may help to define which test is optimal to use with infants with 
Pompe disease in clinical research and early intervention.  
  The PEDI focuses on level of independence in mobility and ADL, but 
research supports a high intra class correlation coefficient for concurrent validity 
with the GMFM, an evaluative tool designed to measure gross motor function.24 
Low correlation coefficients were found between the PEDI and the PDMS-2 in 
children with mild motor impairment. Higher correlations may be found in this 
population with a more notable level of developmental disability.  High correlation 
coefficients with the PEDI functional skills mobility domain would provide 
increased validity for use of the PDMS-2 in children with Pompe disease.   
 The PPEDI includes all of the items listed in the PEDI as well as 59 
additional items that are designed to reflect clinically relevant skills for children 
with Pompe disease. Many of the additional mobility items that were added are 
similar to items that are on the locomotion and stationary subtest of the PDMS-2.  
A strong relationship in concurrent validity testing between the PDMS-2 and the 
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PPEDI would also provide increased validity for PDMS-2 use in children with 
Pompe disease.  
 Established instrument validity for use in Pompe disease is necessary to 
accurately document disease history, guide clinical trial protocol design, evaluate 
efficacy of the intervention, and supplement clinical decision-making. 
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